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resumo 
 
O presente trabalho está dividido em duas partes: a primeira parte centra-se na 
utilização de vírus, mais concretamente bacteriófagos como meio terapêutico, 
já a segunda parte centra-se num estudo epidemiológico feito em parceria com 
o laboratório de análises clínicas Avelab, em que a prevalência dos vírus da 
hepatite A e C entre os anos 2002 e 2012 é evidenciada. 
Enterobacter cloacae faz parte da flora microbiana normal do trato 
gastrointestinal de 40-80% da população. Este microrganismo oportunista é 
capaz de causar infeção em pacientes debilitados e hospitalizados. E. cloacae 
é resistente a um vasto número de antibióticos e por conseguinte as infeções 
causadas por esta bactéria são difíceis de controlar. Neste sentido, a aplicação 
da terapia fágica poderá ser uma possível alternativa no controlo da infeção. A 
sobrevivência e a dinâmica fago-hospedeiro foram testadas em três fagos 
previamente isolados (E-2, E-3 e E-4). A sobrevivência foi testada em PBS pelo 
método de quantificação em dupla camada de agar. A dinâmica de interação 
fago-hospedeiro foi caracterizada em meio de cultura Caldo de Soja 
Tripticaseína e da quantificação dos fagos pela técnica da dupla camada de 
agar. A dinâmica de interação fago-hospedeiro foi testada em PBS e urina. 
Relativamente à sobrevivência dos fagos observou-se o decréscimo da 
concentração de E-2 em duas ordens de grandeza em 105 dias. A 
concentração de E-3 diminuiu em seis ordens de grandeza em 160 dias, 
enquanto a concentração de E-4 diminuiu apenas em uma ordem de grandeza 
em 255 dias. A bactéria foi inibida pelos três fagos, resultando no decréscimo 
de ≈ 3 log após 4-10 h de incubação. O uso de cocktails foi mais eficaz 
observando-se uma redução de ≈ 4 log após 4 h. Na urina a inativação do 
hospedeiro não foi tão eficaz, sendo aproximadamente 2 log. Os fagos E-2, E-3 
e E-4 demonstraram ser eficientes na inativação de E. cloacae sendo 
potenciais agentes no controlo de infeções nosocomiais.  
A hepatite A é uma doença hepática viral comum e tem trazido graves 
problemas de saúde e económicos à medida que o seu padrão epidemiológico 
muda ao longo do tempo. Inquéritos sorológicos de países desenvolvidos 
indicam um declínio da seroprevalência do vírus da hepatite A (VHA) devido à 
melhoria das condições económicas e de saneamento. O vírus da hepatite C 
(VHC) é uma causa importante de doença do fígado em todo o mundo e causa 
de morbilidade e mortalidade substanciais. Na ausência de uma vacina, a 
prevenção é extremamente importante, especialmente para os grupos de risco. 
A taxa de infeção da hepatite C e a taxa de imunidade à hepatite A foram 
pesquisadas ao longo de um período de onze anos, por sexo e faixa etária no 
Distrito de Aveiro. Neste estudo retrospetivo, amostras de sangue de pacientes 
do Distrito de Aveiro, em regime ambulatório, provenientes do Laboratório de 
Análises Clínicas Avelab, foram analisadas para a presença de anticorpos 
contra antigénios do VHA e do VHC através de um imunoensaio de 
quimiluminescência. A imunidade para o VHA foi de 60%. A imunidade foi 
dependente da idade (p < 0.05) mas não se observaram diferenças 
significativas entre sexos nem durante o período de estudo (p >0.05). Cerca de 
4% dos pacientes apresentaram anticorpos anti-VHC. A infeção pelo VHC foi 
dependente da idade e variou entre os sexos (p < 0,05), para além disso 
diminuiu durante o período de estudo (p < 0,05). Os resultados apresentados 
neste estudo indicam que o número de pacientes jovens imunes ao VHA é 
baixo podendo indicar um maior impacto da doença no futuro. Relativamente à 
infeção pelo VHC conclui-se que os homens de meia-idade são mais afetados 
do que as mulheres o que pode indicar que esse grupo é mais propenso a 
comportamentos de risco. Para além disso, a diminuição dos casos positivos 
ao longo do período de estudo pode indicar uma diminuição na exposição a 
fatores de risco. 
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abstract 
 
The present study is divided into two parts: the first part focuses on the use of 
viruses, specifically bacteriophages as an antimicrobial therapy, and the second 
part focuses on an epidemiological study conducted in partnership with the 
Clinical Laboratory Avelab, in which the prevalence of hepatitis A and C viruses 
between 2002 and 2012 is demonstrated. 
Enterobacter cloacae is part of the normal flora of the gastrointestinal tract of 40 
- 80% of people. This opportunistic microorganism is capable of causing 
infection in debilitated and hospitalized patients, such as urinary tract infections 
(UTI) associated with the use of urethral catheters. E. cloacae is resistant to a 
broad number of antibiotics therefore infections caused by this bacterium are 
difficult to control. Phage therapy may be a useful tool to control infections 
caused by antibiotic resistant strains. Three previously isolated phages E-2, E-3 
and E-4 produced on E. cloacae were used to examine survival and host-phage 
dynamics in a buffer solution and in urine in order to evaluate their ability to 
treat UTI. The survival was determined in phosphate buffered saline (PBS) 
through quantification by soft agar overlay technique. The host-phage dynamics 
was characterized in Tryptic Soy Broth (TSB) medium and in human urine 
samples. The concentration of E-2 decreased by two orders of magnitude in the 
first 105 days. E-3 was not detectable after 160 days. E-4 concentration only 
decreased by one order of magnitude after 255 days. The results show that the 
growth of the E. cloacae was inhibited by the three phages, resulting in a 
decrease of ≈ 3 log after 4 - 10 h of incubation. The use of cocktails with two or 
three phages was significantly more effective, namely the phage cocktail E-2/E-
4, with reductions of ≈ 4 log after only 2 hours of treatment. In urine, although 
the phage cocktail E-2/E-4 was less efficient in E. cloacae inactivation than in 
PBS, the inactivation was effective, bacterial reduction of 2.3 log after 4 h of 
incubation. Phages E-2, E-3 and E-4 showed an efficient inactivation of E. 
cloacae, namely when used as phage cocktails, being potential candidates as 
agents for the control of nosocomial urinary tract infections caused by 
Enterobacter cloacae. 
Hepatitis A is a common viral liver disease and brings serious health and 
economic problems as its epidemiologic pattern changes over time. National 
serosurveys from developed countries have indicated a decline in HAV 
(hepatitis A virus) seroprevalence over time due to the improvement of 
economic and sanitation levels. The hepatitis A virus (HAV) immunity rate was 
surveyed throughout an eleven-year period by sex and age group in Aveiro 
District. Hepatitis C virus (HCV) is a major cause of liver disease worldwide and 
causes substantial morbidity and mortality. The common absence of symptoms 
associated leads to uncertainty to the geographic distribution of this disease. In 
the absence of a vaccine and effective treatment, prevention is extremely 
important, especially for at risk groups. The immunity rate of hepatitis A and the 
infection rate of Hepatitis C were surveyed over a period of eleven years by sex 
and age group in the district of Aveiro. In this retrospective study, blood 
samples from patients in ambulatory regime from the Laboratory of Clinical 
Analysis Avelab, were analyzed for the presence of antibodies against antigens 
of HAV and HCV using a chemiluminescence immunoassay. The HAV immunity 
was 60%. The immunity was age dependent (p <0.05) but no significant 
differences were noted between sexes or during the study period (p> 0.05). 
About 4% of patients had anti-HCV antibodies. HCV infection was age and 
gender-dependent (p <0.05) and decreased during the study period (p <0.05). 
The results presented in this study indicate that the immunity for HAV in young 
patients is low and may indicate a greater impact of the disease in the future. 
Regarding HCV infection is concluded that middle-aged men are more affected 
by HCV than women which may indicate that this group is more prone to risky 
behavior. In addition, the reduction of infection rate throughout the study period 
may indicate a decrease in exposure to risk factors. 
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Thesis outline 
This thesis documents two different studies, both related to viruses. In these 
studies, viruses are considered both as therapeutic and infectious agents. 
This document is divided into two parts, with different general purposes. Both parts 
begin with general literature reviews serving as a basis for the following experimental work 
(chapters 1 and 3). 
In the first part (chapter 1 and 2) the efficiency of phage therapy in growth control 
of a pathogen with increasing importance in the hospital environment is tested, in order to 
assess their applicability in the treatment of urinary tract infections. 
In the second part (chapter 3 to 5) a serosurvey was conducted in partnership with 
the clinical laboratory Avelab in order to assess the prevalence of hepatitis A and hepatitis 
C in the District of Aveiro between 2002 and 2012. 
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Chapter 1 - Introduction 
 
1. Bacterial resistance to antibiotics 
The resistance of a bacterium to an antimicrobial drug can result from intrinsic or 
acquired mechanisms. The intrinsic mechanisms occur naturally in genes located on the 
bacterial chromosome and are therefore inherent to bacteria. These intrinsic mechanisms 
are related to the absence of the target or with the presence of low affinity targets, low cell 
permeability and also to multidrug efflux systems of multiresistant bacteria (Ammor, 
Gueimonde et al. 2008). Thus, in the natural resistance, the bacterium is always resistant 
to the antimicrobial drug. On the other hand, in acquired resistance, the bacterium is 
initially sensitive to a particular antibiotic but due to various mechanisms it becomes 
resistant (Bockstael and Van Aerschot 2009). Acquired antimicrobial resistance can occur 
due to a mutation in the gene of the chromosome consisting of the antibiotic target or by 
horizontal transfer of genes, specifically mobile genetic elements that are most likely to be 
transmitted (Alekshun and Levy 2007). The antimicrobial resistance mechanisms and 
examples of resistant bacteria are described in Table 1 (Mulvey and Simor 2009). 
Table 1 - Antimicrobial resistance mechanisms and respective examples (adapted from 
Mulvey & Simor, 2009) 
Mechanism Resistant microorganisms 
Antibiotics affected by 
bacterial resistance 
Antimicrobial inactivation 
β-lactamase 
 
 
 
Enzymatic inactivation of 
aminoglycosides 
 
 Staphylococcus aureus 
 Haemophilus influenza 
 Enterobacteriaceae 
 
 Enterobacteriaceae 
 
 Penicillins 
 Cephalosporins 
 
 
 Gentamicin 
 Tobramicin 
Altered target site 
Altered penicillin-binding 
proteins 
 
 
Altered DNA gyrase or  
topoisomerase 
 
 S. pneumonia 
 Methicillin-resistant S. 
aureus 
 
 
 S. pneumoniae  
 Enterobacteriaceae  
 Pseudomonas aeruginosa 
 
 Penicillin 
 Methicillin 
 Cloxacillin 
 
 Ciprofloxacin  
 Levofloxacin  
 Moxifloxacin 
Decreased access to the target 
site 
Change in outer 
membrane proteins or 
porins 
 
Efflux pump 
 
 Enterobacteriaceae 
 P. aeruginosa 
 
 
 S. aureus  
 Streptococci 
 
 Gentamicin  
 Tobramycin 
 
 Tetracycline  
 Clindamycin  
 Erythromycin 
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Genes that confer bacterial resistance to antimicrobial drugs can be disseminated. 
With some exceptions, the intrinsic resistance and the resistance resulting from a 
mutation are resistance mechanisms that are unlikely to be transmitted (Alekshun and 
Levy 2007). The most frequent mechanism of acquisition of resistance genes corresponds 
to horizontal transfer which may occur within the same strain or between different strains 
or even different bacterial genus. There are three different mechanisms of horizontal gene 
transfer (Figure 1). 
During transformation bacteria capture and incorporate segments of DNA from 
bacterial lysates, the resistance gene may be incorporated into the chromosome or 
plasmid in the recipient cell. When the transfer of these resistance genes is mediated by 
bacteriophages is called transduction. In conjugation acquisition of resistance genes 
occurs as a result of direct contact of two bacterial cells. Plasmids, transposons or 
integrons move into the recipient cell. Plasmids are the only ones able to replicate 
autonomously. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Importance of Enterobacter cloacae infection 
Enterobacter cloacae belongs to Enterobacter genus and Enterobacteriaceae 
family. It is distinguished from the genus Klebsiela by its motility and is usually ornithine 
decarboxylase positive and urease negative (Kosako, Tamura et al. 1996). The most 
frequent human pathogens from Enterobacter genus are E. aerogenes and E. cloacae. E. 
cloacae is several times a cause of nosocomial infections. There is not much information 
Figure 1 - Horizontal gene transfer between bacteria 
(adapted from Furuya et al., 2006) 
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about the factors leading to its pathogenicity and virulence. As a Gram-negative pathogen, 
E. cloacae possess endotoxins and thus may have pathogenic characteristics similar to 
other Gram-negative pathogens. E. cloacae is responsible for respiratory tract, urinary 
tract and intra-abdominal infections, endocarditis, septic arthritis, osteomyelitis and skin 
and soft tissue infections (Jeong, Lee et al. 2003). 
In preantibiotic era, it was not considered in surveys of nosocomial bacteremia 
(McGowan 1988). However, the importance of this infection was highlighted in the most 
recent National Healthcare Safety Network at the Centers for Disease Control and 
Prevention (NHSN) data. In this survey, 2,039 hospitals reported nosocomial infections 
and 5% of them were caused by Enterobacter spp. Nearly 20% of total pathogens 
reported were multidrug resistant and 2% of total pathogens were extended-spectrum 
cephalosporin–resistant Enterobacter spp (Sievert, Ricks et al. 2013). 
In another study the increasing importance of Enterobacter spp. was most 
apparent when isolates from intensive care units (ICU) were considered separately from 
the hospital at large. Enterobacter spp. was the third most common pathogen isolated 
from respiratory tract, the fourth most common from cirurgical wounds and the fifth most 
common from the urinary tract. Patients at increased risk of acquiring E. cloacae infection 
are those with a prolonged hospital stay, especially at ICU (Sanders and Sanders 1997). 
There are several studies proving E. cloacae resistance to β-lactams, fluoroquinilones, 
aminoglycosides and tigecycline (Périchon, Courvalin et al. 2007, Pitout and Laupland 
2008). 
3. Enterobacter cloacae and urinary tract infections 
The bladder is typically sterile, but the epithelial cells coating the urethra, 
downstream, are colonized by rods and aerobic facultative gram-negative cocci (Madigan 
et al 2009). The presence of microorganisms in the terminal urethra, and its consequent 
multiplication and invasion of tissues can cause the onset of a UTI (urinary tract infection). 
A set of structural, functional and physiologic factors in the urinary tract can play a key 
role in the development of the infection. Bacterial growth may be promoted by the 
presence of certain nutrients, such as glucose, amino acids and uric acid in urine and by 
an increase in its pH (Zasloff 2007). The presence of 105 CFU mL-1 of the same organism 
in a sample of urine is defined by significant bacteriuria (Raju and Tiwari 2001). 
 Pathogens belonging to the genus Enterobacter are some of the most commonly 
found in urinary infections Linhares et al., conducted a study in ambulatory regime in 
Aveiro wherein Enterobacter spp showed high resistance (greater than 80%) to 1st and 2nd 
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generation cephalosporins, amoxicillin and amoxicillin + clavulanic acid (Linhares, Raposo 
et al. 2013). 
Urinary tract infection associated with urethral catheters are the most common 
infections occurring during hospitalization accounting for up to 40% of all nosocomial 
infections (Kunin 1997). The Enterobactericae are the most common pathogen in 
catheterized patients. There are reports indicating a relation between catheterized 
patients and bloodstream infection caused by E. cloacae (Tambyah and Maki 2000). E. 
cloacae infections have the highest mortality rate compared to 
other Enterobacter infections (Kanemitsu, Endo et al. 2007). 
 
4. Bacteriophages 
 
4.1 Discovery of Bacteriophages 
In 1896 Ernest Hanking in England reported the observation of high antibacterial 
activity against Vibrio cholerae in the waters of the Ganges (Deresinski 2009). Faced with 
this phenomenon Ernest Hanking suggested an unknown substance that would be 
primarily responsible for the high antibacterial activity, thus restricting the spread of 
epidemics of cholera (Summers 2005). Two years later Gamaleya, Russia, observed a 
similar phenomenon with Bacillus subtilis (Dublanchet and Fruciano 2008). At the 
beginning of the twentieth century, Frederick Twort and Felix d'Herelle, independently, 
described entities that could destroy cultures of bacteria. D'Herelle named them 
bacteriophages and developed the method of quantification of viruses and some theories, 
including the replication cycle of the phage (Bratbak, Egge et al. 1993). The name 
bacteriophage was formed from “bacteria” and “phagein” (“to eat”, in Greek) 
(Sulakvelidze, Alavidze et al. 2001).  
4.2 Properties and classification of bacteriophages 
Bacteriophages are constituted by one order and 17 families (Table 2). 
Bacteriophage taxonomy is based on their shape, size and proteins as well as on their 
nucleic acid. Bacteriophages are tailed, polyhedral, filamentous, or pleomorphic (Figure 
2). Most bacteriophages contain dsDNA, but there are phages with ssDNA, ssRNA or 
dsRNA (Ackermann 2003, Ackermann 2007). 
 
  
 
9 
 
Table 2 - Basic properties of bacteriophages and their classification (adapted from 
Ackermann, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.1 Bacteriophage infection 
Phages are metabolically inert in their extra cellular form. They are only able to 
self-reproduce as long as the host is present and their replication depends exclusively on 
Shape Nucleic acid Order and 
families 
Characteristics 
Tailed dsDNA linear Myoviridae Tail contractile 
Siphoviridae Tail long, noncontractile 
Podoviridae Tail short 
Polyhedral ssDNA, Circular Microviridae Capsomers 
dsDNA, Circular, Superhelical Corticoviridae Complex capsid, lipids 
dsDNA, Linear Tectiviridae Inner lipoprotein vescicle, pseudotail 
ssRNA, Linear Leviviridae Polivirus-like 
Filamentous dsRNA, Linear, Segmented Cystoviridae Envelope, lipids 
ssDNA, Circular Inoviridae Long filaments, short rods 
dsDNA, Linear Lipothrixviridae Envelope, lipids 
dsDNA, Linear Rudiviridae TMV-like 
Pleomorphic dsDNA, circular superhelical Plasmaviridae Envelope, lipids, no capsid 
dsDNA, Circular superhelical Fuselloviridae Lemon-shaped 
dsDNA, linear superhelical Saltepovirus Lemon-shaped 
dsDNA, circular superhelical Guttaviridae Droplet-shaped 
Figure 2 - Representation of phage families (Ackermann, 2007). 
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the host intracellular machinery to translate their own genetic code (Lorch 1999). Viruses 
can interact with their hosts in two major and distinctive ways, the lytic and lysogenic 
cycles of infection and more sporadically through pseudolysogeny (Figure 3) (Almeida, 
Cunha et al. 2009). Only lytic phages are suitable candidates for phage therapy since they 
may destroy bacteria (Weinbauer and Rassoulzadegan 2004). 
In the lytic cycle, firstly phages bind to specific receptors of bacteria. This stage is 
called adsorption. Phages can use different parts of lipopolysaccharide (LPS), flagella, 
fimbriae and many other surface proteins as receptors. Bacteriophages may also use 
enzymes to break down the bacterial surface (Skurnik and Strauch 2006, Wróblewska 
2006). Then they multiply in the host cell after the genome is injected into the host 
bacterium. Most of the proteins produced in this phase are involved in the shutting down 
of the host bacterium systems and phage genome replication. In some cases, the early 
proteins degrade the host DNA (Weinbauer 2004, Goodridge 2010). The expression of the 
phage late proteins involved in the formation of new phage particles is responsible for the 
cell lysis (Duckworth and Gulig 2002). Fifty to 200 particles are released during lysis (Huff, 
Huff et al. 2005). 
In the lysogenic cycle, the virus enters its genetic material into the host cell, that is, 
the viral DNA becomes part of the infected cell DNA. The genetic material of the 
bacteriophage, called prophage, can be transmitted to daughter cells. Occasionally, due 
to external factors (e.g. UV light), spontaneous lysis occurs and progeny phage is 
released (Hanlon 2007). Lysogeny might be a viral strategy that allows survival in periods 
of low host density during nutrient starvation (Weinbauer 2004). 
Pseudo-lysogeny is another phenomenon that describes a phage-host cell 
interaction in which the nucleic acid of the phage, upon infection of an appropriate host 
cell, neither establishes a stable relationship nor triggers a lytic response. The phage 
nucleic acid simply resides within the cell in a non-active state. In situations of low 
nutrition there is insufficient energy available for the phage to initiate the typical responses 
of infection. However, when the level of nutrient availability increases, the phage acquires 
the necessary energy to allow gene expression, leading to either the establishment of a 
state of true lysogeny or replication and expression of the viral genome, leading to virion 
formation and lysis of the host cell (Ripp and Miller 1998). 
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4.3  Phage Therapy 
Phage therapy consists in the use of bacteriophages to inactivate bacteria 
(Almeida, Cunha et al. 2009). Since bacteriophages discovery, phage therapy was 
vigorously investigated, but after antibiotic advent the interest in phage-based 
therapeutics declined in the western world (Sulakvelidze, Alavidze et al. 2001). 
Nevertheless, in former Soviet Union countries, this therapy was continuously used and 
many progresses have been made (Summers 2001). 
4.3.1 Prerequisites for phage therapy 
Phage production is not simple and when this therapy was first applied clinically 
side effects were difficult to control. There are some requirements in the production of 
phages (Skurnik and Strauch 2006). 
 Phages must be free from microorganisms; 
 Phages must be well characterized. The genome must be sequenced in order to 
avoid resistance and toxin transmission to bacteria; 
 Phages must be lytic and non-temperate; 
 Phages must not transduce virulence factor genes of the host; 
 The receiver of the phage must be known. In a population of 106 to 108 there is a 
great possibility of spontaneous mutants resistant to phages displaying an altered 
receptor; 
 The broad host range must be well known; 
 Stability of the phages over storage and application must be tested; 
 Amenability to scale up. 
Figure 3 - Representation of phage families (Ackermann, 2007). 
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4.3.2 Advantages and disadvantages of phage therapy 
The emergence of pathogenic bacteria resistant to most, if not all, currently 
available antimicrobial agents has become a critical problem in modern medicine. Since 
apparently we are reentering the “preantibiotics” era the development of alternative 
antibacterial therapies is imperative. Nowadays, western countries renewed the interest in 
phage therapy (Sulakvelidze, Alavidze et al. 2001). 
Advantages 
Phage therapy represents a potentially viable alternative to antibiotics and to other 
antibacterial compounds to inactivate pathogenic bacteria (Almeida, Cunha et al. 2009). 
There are many advantages of bacteriophages over antibiotics (Table 3). 
Table 3 - Major advantages of phage therapy against antibiotics (Adapted from Abedon & 
Thomas-Abedon, 2010, Hagens and Loessner, 2010, Harcombe and Bull, 2005, Matsuzaki et 
al., 2005, Skurnik and Strauch, 2006). 
Advantages of phage therapy against antibiotics 
 Phages are specific to target. The broad host-range usually includes the level of 
strain and rarely the level of genus. The restricted host specificity means that 
phages generally will not affect beneficial bacteria, like commensals in the 
gastrointestinal tract; 
 Phages have limited resistance development compared to antibiotics; 
 No serious side-effects have been described since phages do not affect eukaryotic 
cells neither natural microflora. The target specificity decrease patient’s side effects 
since the natural flora is not disturbed; 
 When resistance occurs, the selection of new phages is a relatively fast process; 
 Attenuates the virulence of bacteria that become resistant to phage; 
 Phages multiply as long as bacteria are present; 
 Low-cost production. 
 
Disadvantages 
Despite the many advantages, there are still some problems associated to this 
therapy. 
It is possible that the release of large amounts of bacterial endotoxins bound to the 
membrane during cell lysis causes side effects, though, purification of the phage 
suspensions is a simple process (Tanji, Shimada et al. 2005). The use of phage therapy is 
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more effective when applied locally, although there are several studies in which systemic 
application has promising results (Gregoracci 2006).  
The lysogenic conversion can be another problem associated to this therapy. The 
lysogeny can induce a phenotype modification of the host cell such as toxin production 
and antibiotic resistance but also resistance to infection by similar phages (Alisky, 
Iczkowski et al. 1998, Skurnik and Strauch 2006). In phage infection there is an 
attachment of the phage onto specific receptors of bacteria. If the mutation of these 
receptors occurs, the phage fails to recognize bacteria (Levin and Bull 2004). Despite this 
obstacle to the application of phage therapy, the induction of resistance of bacteria is not 
considered a major concern, since a wide range of studies show that the mutation rate of 
phage accompanies the mutation rate of bacteria, sufficiently to maintain the effectiveness 
of phage therapy (Parisien, Allain et al. 2008). Furthermore, it is possible that the receptor 
used by the phage is a virulence determinant thus the loss of receptor would reduce the 
virulence of bacteria, then it would be easier for the host immune system to overcome the 
infection (Skurnik and Strauch 2006). It is also possible to use cocktails of phages in order 
to avoid resistance (Chan and Abedon 2012, Mateus, Costa et al. 2014). 
4.3.3. Clinical applications of phage therapy 
  Immediately after the discovery of bacteriophages, although surrounded in 
mysticism regarding the nature and potential therapeutic properties, phage therapy was 
used in benefit of man (Gregoracci 2006). 
  During the summer of 1919, d'Herelle applied phage therapy in five children with 
bacillary dysentery admitted at the hospital Necker-Enfants-Malades in France, achieving 
therapeutic success in all cases (Dublanchet and Bourne 2007). 
  Since western countries abandoned phage therapy, the  majority  of  studies  
demonstrating  the  efficacy  of  phage  therapy  in  clinical  settings came from research 
groups in Eastern Europe and the former Soviet Union and were published in  non-English 
journals (Sulakvelidze, Alavidze et al. 2001). 
  Most of the actual knowledge regarding clinical applications of phages comes 
Eliava Institute of Bacteriophage, Microbiology and Virology in Georgia. Thousands of 
monophages and cocktail of phages (pyophage and intestiphage) for pathogenic bacteria 
strains, such as Staphylococcus, Streptococcus, Proteus, Pseudomonas aeruginosa and 
Clostridium were prepared in this Institute (Lorch 1999, Kutateladze and Adamia 2008). 
They continually renewed the cocktail pyophage and intestiphage with new phages 
against recently virulent strains for wound infections and enteric bacteria, respectively. For 
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deeper wounds, phages embedded in polymer called PhageBioderm is often used in 
addition to pyophage.  PhageBioderm is a biodegradable, non-toxic polymer developed by 
Georgian chemists and microbiologists in 1995 and approved for commercial release in 
2000 (Kutter, De Vos et al. 2010). 
  In the Institute for Immunology and Experimental Medicine in Poland there is a 
bank of phages constituted by 300 specific bacteriophage strains against Staphylococci, 
Enterococci, Escherichia sp., Klebsiella sp., Salmonella sp., Shigella sp., Enterobacter 
sp., Proteus sp., Serratia sp., Acinetobacter sp. and Pseudomonas sp. (Kutter, De Vos et 
al. 2010).  
  The literature provided by these countries show that the bacteriophages have 
potential as antimicrobial agents. Soviet and Polish studies were mostly clinical, contrary 
to most Western Europe countries studies. They found efficacy against mucosal, systemic 
and cutaneous infections, including in immunosuppressed patients. These studies showed 
rare and reversible side effects (Slopek, Durlakowa et al. 1983, Sulakvelidze, Alavidze et 
al. 2001). 
 In western countries phage therapy is recently gaining interest. Studies related to 
phage kinetics, especially the multiplicity of infection (MOI) that is, the prediction on the 
number of phage dose applications and the timing of application, are currently being done 
(Levin and Bull 2004). 
4.3.4. Other applications of phage therapy 
Phage therapy is also being extensively studied in other industries. In table 4 are 
described companies that commercialize phages or phage products for various sectors.  
 Aquaculture 
Aquaculture is characterized by production of all types of cultured aquatic animals 
and plants in brackish water, freshwater and marine water (Pillay and Kutty 2005). Despite 
the rapid development of this industry, its vulnerability to infections leads to considerable 
losses (Flegel 2006, Saksida 2006). The development of infections caused by 
microorganisms, including multiresistant bacteria, is readily transmitted by water, infecting 
a variety of fish species (Almeida, Cunha et al. 2009). Since the rate of resistance to 
antibiotics in this sector is increasingly high, there has been much interest in finding 
phages to treat the main diseases affecting aquaculture. A group of Japanese researchers 
studied the potential use of phages to prevent infections in fish caused by Lactococcus 
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garviae and concluded that the use of phages can be useful to control infections in fish 
cultures (Skurnik and Strauch 2006, Almeida, Cunha et al. 2009). 
 Veterinary 
Phage therapy is also used to control animal infections. The most successful 
cases reported relate to the use of phage against Salmonella infections in poultry and in 
cases of enteritis neonatal caused by Escherichia coli in calves, piglets and lambs, with 
promising results (Atterbury 2009, Henriques, Sereno et al. 2013). 
 Agriculture 
The main infections in plants are of fungal origin, however bacterial infections are 
responsible for the major losses in agriculture (Balogh, Jones et al. 2010). These 
infections are often difficult to control due to lack of effective bactericide (Obradovic, 
Jones et al. 2005). In order to overcome this problem phages have been recently 
evaluated to control some phytobacteria (Balogh, Canteros et al. 2008, Balogh, Jones et 
al. 2010). An available example of a phage suspension is agrifago that is effective and 
safe for prevention and control of harmful bacteria in tomato and pepper cultures (Housby 
and Mann 2009). 
 Food industry 
The use of phage in the food industry is currently applied as a biological control 
method for undesirable pathogens, increasing food security, in particular fresh and ready-
to-eat foods (Hagens and Loessner 2010). The food industry focuses its interest in four 
pathogens (Listeria monocytogenes, Salmonella, Campylobacter and Escherichia coli) 
(Rees and Dodd 2006). In 2006, the FDA and the American Agriculture Department 
approved a phage suspension anti-Listeria that can be used as an aid in processing of all 
food products susceptible to Listeria monocytogenes (Hagens and Loessner 2010). 
Table 4 - Leading companies related to the commercialization of phage products (adapted 
from Housby and Mann, 2009). 
Company (location) Product area Stage of development 
BigDNA 
 (Edinburgh, UK) 
Bacteriophage DNA vaccination via 
phage encoded DNA delivered 
intravenously or orally 
R&D 
Blaze Venture Technologies 
(Hertfordshire, UK) 
Phage immobilization technology, 
MRSA, licensing 
Licensing 
JSC Biochimpharm 
(Tbilisi, Republic of Georgia) 
Various phage lysates are mixed and 
used for intestinal problems, 
for example, Dysentery, salmonellosis, 
Commercialization 
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dyspepsia, colitis and 
enterocolitis and for bacterial infections. 
Biopharm L Limited 
(Tbilisi, Republic of Georgia) 
Products include Pyobacteriophage and 
Intesti-bacteriophage that 
are mixtures of phage lysates for 
bacterial intestinal and infection 
control-sold to pharmacies as Over The 
Counter drugs. 
Commercialization 
BioControl  
(Southampton, UK) 
Pseudomonas infections of the ear Phase II trial completed 
Biophage Pharma Inc. 
(Montreal, Canada) 
Environmental therapies and 
diagnostics, phage products geared 
towards antibacterial resistance 
problems and as a weapon against 
bioterrorism 
Research and 
development 
EBI Food Safety 
(Wageningen, Netherlands) 
Food Safety. A cocktail of phage against 
Listeria 
LISTEX P100
TM
,  
Product available 
Gangagen  
(Bangalore, India and 
Palo Alto, California, USA) 
Staphylococcus aureus Pre-clinical 
Innophage  
(Porto, Portugal) 
Environment, Cosmetic and Medical 
bacterial infections 
Unknown 
Intralytix  
(Baltimore, USA) 
Food safety, Listeria 
FDA and EMEA approval 
on ready to eat meats 
and cheeses 
Neurophage Pharmaceuticals 
(Cambridge, USA) 
Brain changes, for example Alzheimer Startup company 
Novolytics 
(Coventry, UK) 
Prevention and treatment of MRSA 
infection 
Pre-clinical 
Omnilytics 
(Salt Lake City, Utah, US) 
AgriPhage is a natural, safe, effective 
treatment that prevents and 
controls harmful bacteria on tomato and 
pepper plants 
Product available 
Phage-Biotech 
(Rehovot, Israel) 
Anti-Pseudomonas infectives R&D 
Phico Therapeutics 
(Cambridge, UK) 
Anti MRSA products Pre-clinical 
Phage International 
(San Ramon, California,USA; 
Tbilisi, Republic of Georgia) 
Phage treatment center Distributor 
Viridax 
(Boca Raton, Florida, USA)  
Staphylococcal aureus—respiratory, 
systemic, topical, wound care 
Pre-clinical 
 
4.3.5. Phage cocktails 
The simultaneous use of two or more phages has been proven more effective than 
the use of monophage therapy (Chan and Abedon 2012). 
The monophage therapy is used when a sufficiently wide host range phage is 
found. This approach is simpler since the preparation of the phage suspension is easier 
and the risk of immunological interaction is lower. The combinations of individual phages 
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isolates broaden the typical narrow spectrum of activity of the single phage. This results in 
increased magnitude of utility for individual formulations to treat specific bacterial diseases 
and prevention of phage-resistant bacteria (Thiel 2004). 
Resistance may result from the alteration or loss of the bacterial cell surface 
receptors, inhibition of phage DNA penetration and production of restriction 
endonucleases which degrade the phage DNA (Labrie, Samson et al. 2010). This 
limitation may be overcame by the combined use of two or more phages (Chan, Abedon 
et al. 2013). 
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1. Abstract 
Enterobacter cloacae is part of the normal flora of the gastrointestinal tract of 40 - 
80% of people. This opportunistic microorganism is capable of causing infection in 
debilitated and hospitalized patients, such as urinary tract infections (UTI) associated with 
the use of urethral catheters. E. cloacae is resistant to a broad number of antibiotics 
therefore infections caused by this bacterium are difficult to control. Phage therapy may 
be a useful tool to control infections caused by antibiotic resistant strains. Three 
previously isolated phages E-2, E-3 and E-4 produced on E. cloacae were used to 
examine survival and host-phage dynamics in a buffer solution and in urine in order to 
evaluate their ability to treat UTI. The survival was determined in phosphate buffered 
saline (PBS) through quantification by soft agar overlay technique. The host-phage 
dynamics was characterized in Tryptic Soy Broth (TSB) medium and in human urine 
samples, through quantification of phages by soft agar overlay technique and host 
quantification in Tryptic Soy Agar (TSA) medium. The concentration of E-2 decreased by 
two orders of magnitude in the first 105 days. The concentration of E-3 decreased by one 
order of magnitude in the first 20 days and reached a plateau until 77 days. Afterwards, 
the phage titer decreased by three orders of magnitude until 156 days. E-4 concentration 
only decreased by one order of magnitude after 255 days. The results show that the 
growth of the E. cloacae was inhibited by the three phages, resulting in a decrease of ≈ 3 
log after 4 - 10 h of incubation. The use of cocktails with two or three phages was 
significantly more effective, namely the phage cocktail E-2/E-4, with reductions of ≈ 4 log 
after only 4 hours of treatment. In urine, although the phage cocktail E-2/E-4 was less 
efficient in E. cloacae inactivation than in PBS, the inactivation was effective, bacterial 
reduction of 2.3 log after 4 h of incubation. Phages E-2, E-3 and E-4 showed an efficient 
inactivation of E. cloacae, namely when used as phage cocktails, being potential 
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candidates as agents for the control of nosocomial urinary tract infections caused by 
Enterobacter cloacae. 
Keywords: Viruses, phage therapy, phage cocktails bacteriophage, Enterobacter 
cloacae, multidrug resistant bacteria, urinary tract infections 
2. Introduction 
Enterobacter cloacae is a Gram-negative pathogen responsible for respiratory 
tract, urinary tract and intra-abdominal infections, endocarditis, septic arthritis, 
osteomyelitis and skin and soft tissue infections and these bacteria are responsible for 
healthcare-associated infections or nosocomial infections (Jeong, Lee et al. 2003). 
Nosocomial infections are acquired during hospital admission or medical procedures and 
have been increasing due to the overuse of antibiotics. According to the latest European 
Centre for Disease Prevention and Control report, from a total of 231 459 patients from 
947 hospitals, the prevalence of patients with at least one nosocomial infection was 6.0%. 
Of a total of 264 infections by E. cloacae reported during 2011, 94 were multi-drug 
resistant (ECDC 2013). 
Urinary tract infection (UTI) associated with urethral catheters are the most 
common infections occurring during hospitalization, accounting for up to 40% of all 
nosocomial infections (Kunin 1997). There are reports indicating a relation between 
catheterized patients and infections caused by E. cloacae (Tambyah and Maki 2000). 
Moreover, E. cloacae infections have the highest mortality rate compared to other 
Enterobacter infections (Kanemitsu, Endo et al. 2007). Phage therapy (use of lytic phages 
to inactivate bacteria) can be used as an alternative to control this nosocomial infection. 
Bacteriophages or phages are viruses that are capable to infect exclusively 
bacteria. Until the advent of antibiotics, phage therapy was widely used, especially in the 
Eastern Europe countries. It fell into disuse and now, due to the overuse of antibiotics and 
consequent appearances of resistant bacteria, a growing interest in this therapy approach 
can be noted (Sulakvelidze, Alavidze et al. 2001, Ackermann 2003, Hanlon 2007). 
The selection of the appropriate bacteriophage is a key factor in the success of the 
phage therapy treatment. Among the main criteria required to select viruses for phage 
therapy are i) host range, ii) survival in the environment; iii) no potential for lysogenic 
conversion and/or generalised transduction and, of course, iv) the efficiency of bacterial 
inactivation (Skurnik and Strauch 2006). 
Therapeutic phages should have a large broad host range which means that 
phages should be able to lyse majority of the strains of a given bacterial species (Almeida, 
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Cunha et al. 2009). Some studies that have focused on the host range of individual 
phages have shown a large variation in phage specificity, both within and across bacterial 
species. In fact, some phages that appear to be broader, in the sense that they can infect 
different genera of bacteria, fail to infect a subset of strains or species within the same 
genus. This is most likely the result of both specific phage adaptations and the 
subsequent evolution of bacterial resistance in some lineages, including via transfer of 
plasmids, which makes difficult to decipher specific rules concerning phage host range 
(Koskella and Meaden 2013). For instance, Jensen et al (1998) have shown that nine of 
ten phages of E. coli, P. aeruginosa and Sphaerotilus natans presented a broad-host-
range, infecting their hosts and bacteria from another orders (such as, Pseudomonadales, 
Burkholderiales or Enterobacteriales) (Jensen, Schrader et al. 1998). However, the 
‘jumbo’ phage RaK2, isolated using Klebsiella sp as host by Šimoliūnas et al (2013), was 
tested on 40 bacterial strains from different genera and 39 of these bacterial strains were 
resistant to the phage RaK2 (Šimoliūnas, Kaliniene et al. 2013). 
The success of phage therapy to control pathogenic bacteria depends on viral 
survival and viability in environment to maintain their lytic attributes. Although there are 
some data available about the study of the mechanisms and rates of mortality or loss of 
infectivity of phages, little is known about their time of survival in the environment. De 
Paepe and Taddei (2006) by comparing life history traits of 16 phages infecting the 
bacterium Escherichia coli, showed that their mortality rate is constant with time and 
negatively correlated to their multiplication rate in the bacterial host. The authors showed 
that the capsid thickness and the density of the packaged genome account for 82% of the 
variation in the mortality rate (De Paepe and Taddei 2006). Tsonos et al (2013) used a 
cocktail of four different phages to cure avian pathogenic Escherichia coli (APEC) infected 
chickens. Although the phages in the cocktail were able to efficiently lyse the APEC strain 
in vitro, treated chickens did not show a significant decrease in mortality, lesion scores or 
weight loss compared to untreated groups, even though the APEC-specific phages could 
be re-isolated from the lung and heart of chickens that were euthanized. Moreover, the re-
isolated bacteria from infected chickens had remained sensitive to the phage cocktail 
(Tsonos, Oosterik et al. 2013).  
To select phages with therapeutic potential it is necessary to assure that there is 
any potential for lysogenic conversion of the phages in order to avoid the expression of 
genes that encoding toxins and to maintain their lytic characteristics so that inactivate 
efficientely the pathogenic bacteria. The potential of lysogenic conversion can be 
evaluated through the detection of genes encoding integrase enzymes. Another concern 
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having into account in the selection of the phages is their generalised transduction which 
can tansmit resistance genes to the bacteria such as antibiotic resistance. (Skurnik and 
Strauch 2006). 
Another major concern regarding the use of phages to control infections is the 
emergency of phage-resistant mutants (Hyman and Abedon 2010). Resistance may result 
from the alteration or loss of the bacterial cell surface receptors; inhibition of phage DNA 
penetration; production of restriction endonucleases which degrade the phage DNA, 
clustered regularly interspaced short palindromic repeats (CRISPR) system, a widespread 
microbial response to by-pass the selective pressure exerted by phage infection, among 
others (Deveau, Garneau et al. 2010). This limitation can be overcame by the combined 
use of two or more phages or phage cocktails (Chan, Abedon et al. 2013). The mutation 
induced by phages may lead also to loss of pathogenic properties (Filippov, Sergueev et 
al. 2011). Another advantage of the use of phage cocktails is the ability of treating multiple 
pathogens, this feature broaden the spectrum of action of phage therapy (Cairns, Timms 
et al. 2009, Kunisaki and Tanji 2010, Chan, Abedon et al. 2013). 
The aim of the present study was to evaluate the effectiveness and safety of 
phage cocktails in order to control UTI caused by E. cloacae. The isolated phages were 
tested separately and combined in PBS and the best phage cocktail was also tested in 
human urine samples. 
3. Material and Methods 
3.1. Bacterial strains and Growth conditions 
The bacterial strain E. cloacae used in study as phage host was previously 
isolated in our laboratory (Pereira, 2014). The bacterial strains used in host range studies 
are listed in Table 5. Salmonella typhimurium (ATCC 13311 and ATCC14028), 
Escherichia coli (ATCC 25922 and 13706), Aeromonas hydrophila (ATCC 7966), 
Staphylococcus aureus (ATCC 6538 and DSM 25693), Vibrio parahaemolyticus (DSM 
27657), Shigella flexnexi (DSM 4782), Listeria innocua (NCTC 11288) and Listeria 
monocytogenes (NCTC1194) were purchased from ATCC, DSM and NCTC collection, 
respectively. Four S. aureus enterotoxic strains (2065 MA, 2153 MA, 2095 MA and 2043 
MA) were isolated from food (Baptista et al, 2015). Five strains Salmonella enteriditis were 
isolated from food given by Controlvet. The other bacterial strains used in this study were 
isolated in other study from water collected in Ria Aveiro (Louvado et al, 2012). The E. 
cloacae isolate were maintained in TSA (Merck, Darmstadt, Germany) at 4 ºC. Before 
each assay, one isolated colony was transferred to 10 mL of TSB (Merck, Darmstadt, 
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Germany) and was grown overnight at 37 °C. An aliquot of this culture (100 μL) was 
aseptically transferred to 10 mL of fresh TSB medium and grown overnight at 37 °C to 
reach an optical density (O.D. 600) of ≈ 0.8. 
3.2. Phage isolation and host range 
A sample of wastewater from a secondary-treated sewage plant near the city of 
Aveiro (Portugal) was used to isolate the E. cloacae bacteriophages according Costa et 
al. (2011). The sewage water was filtered sequentially by 3 µm and then 0.45 µm-pore-
size polycarbonate membranes. The filtrate was added to a fresh bacterial culture in 
double concentrated TSB. The mixture was incubated at 37 ºC for 5 hours and then 
centrifuged (10,000 x g, 10 minutes). The phage titer was determined by the double-layer 
method (Adams 1959) using the centrifuged supernatant as phage suspension and TSA 
as culture medium. The plates were incubated at 37 ºC and examined for lysis plaques 
after 12 hours. Two more successive single-plaque isolations were performed to obtain 
pure phage suspensions. Phage suspensions were stored at 4 °C with 1% of chloroform 
(Scharlau, Spain). 
Phage host range was determined by the spot test. Ten microliters of concentrated 
phage lysate (>109 PFU mL-1) was dropped onto a TSA plate overlaid with E. cloacae (108 
CFU mL-1). The plate was allowed to dry and incubated for 8 - 12 h. According to the 
degrees of clarity, the spots were differentiated into three categories: large clear (++), 
small clear lysis (+), not lysis (-). Bacterial susceptibility to the three bacteriophages was 
assayed for 47 pathogenic bacterial strains (Table 5). The hosts tested included species 
from 15 genera. 
3.3. Phage survival determination 
Phage survival was tested in phosphate buffered saline (PBS). Phage 
suspensions were added (estimated final concentration 107 PFU mL−1) and incubated at 
25 °C without shaking. The phage titer was determined as described above, at time zero 
and at intervals of 12 h until day 1, 24 h until day 5, 48 h until day 9, 72 h until day 12, 120 
h until day 45, and 240 h until the end of the experiment (day 255), by the double-layer 
method.  The plates were incubated at 37 °C and examined for plaques after 4 - 8 h. For 
each phage, three independent experiments were done.  
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3.4. Phage DNA extraction 
Bacteriophage lysates (109 plaque forming units, PFU mL-1) were centrifuged 3 
times at 6000 g for 10 min. The phage lysates were ultracentrifuged at 100000 g for 2 h at 
10 ºC. Five hundred microliters of SM buffer were added to the pellet and was let to rest 
for 2 h. The suspension was then treated with DNase I and RNase A at 37 °C for 20 min 
to remove any free nucleic acids contamination. Nucleic acid extraction from phage 
particles was performed as described by Griffiths et al. [38]. Extraction was performed by 
the addition of 0.5 mL of hexadecyltrimethylammonium bromide (Sigma Aldrich, St. Louis, 
MO, USA) extraction buffer and 0.5 mL of phenol-chloroform-isoamyl alcohol (25:24:1; pH 
8.0; Sigma Aldrich) to the sample. The sample was lysed for 30 s in a FastPrep FP120 
(BIO 101/Savant) at 5.5 ms−1 and centrifuged (16,000 g) for 5 min at 4 °C. The 
supernatant was pipetted into a clean vial, mixed 1:1 with chloroform-isoamyl alcohol 
(Sigma Aldrich) and centrifuged (16,000 g) for 5 min at 4 °C. The supernatant was 
removed to a clean tube and the nucleic acids were precipitated with two volumes of 30% 
(wt/v) polyethylene glycol 6000 – 1.6 M NaCl for 2 h at 25°C. This mixture was centrifuged 
(18,000 g) at 4 °C for 10 min, the pellet washed in ice cold 70% (v/v) ethanol, centrifuged 
(18.000 g) at 4 °C for 10 min and then the pellet was air dried prior to re-suspension in 30 
µL Tris-EDTA buffer. Nucleic acid yield was quantified in the Qubit 2.0 Fluorometer 
(Invitrogen, Carlsbad, CA, USA). The resulting product was electrophoresed through 0.8 
% agarose gel at 80 V for 40 min. 
3.5. Whole genome sequencing and bioinformatics analyses 
Ten µg of DNA of each purified phage were subjected to a Roche/454 
pyrosequencing approach on a GS FLX device with Titanium reagents. The six samples 
were barcoded and pooled on 1/4 of the sequencing plate. Reads were assembled using 
CLC Genomics Workbench version 7 (CLCbio, Aarhus, Denmark) and Roche 
GSAssembler version 2.7 (Roche, Switzerland). 
3.6. Kill curves in PBS 
The three phages (E-2, E-3 and E-4) were separately tested and phage cocktails 
were tested (two or three phages mixed together at the same concentration). In all assays 
E. cloacae was used as host at a MOI of 100. In order to obtain a MOI of 100, 2,5 μL of E. 
cloacae culture at a concentration of 108 CFU ml-1 and the phage suspension at a 
concentration of 109 PFU mL−1 were added to sterilized Erlenmeyers with 30 mL of TSB 
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medium and incubated at 37 ºC overnight. Before each phage therapy assays, the phage 
titer was determined using the double agar layer method, after an incubation period of 4–6 
h at 37 °C. For each assay two control samples were preformed, the phage control (PC) 
and the bacterial control (BC) and the incubation conditions were exactly the same. After 
0, 2, 4, 6, 8, 10, 12 and 24 hours aliquots of test samples and of bacterial and phage 
controls were collected to quantify bacteria and phages, respectively. 
3.7. Kill curves in urine 
To perform phage therapy in urine, the cocktail with higher efficiency was tested in 
urine instead of PBS at a MOI of 100 and the phages were also tested separately. The 
urine samples were ceded by Laboratory of Clinical Analysis Avelab (Aveiro, Portugal). 
The study was approved by the Ethical Committee of the Clinical Analysis Laboratory 
Avelab, specifically by Doctors Alberto Ferreira Neves, António Rodrigues and Maria 
Teresa Raposo. Early urine samples were collected, using the Avelab Laboratory 
protocol, by midstream clean-catch technique after patient daily hygiene. The middle jact 
was collected directly into the sterile recipient. The urine samples presented a pH of 6, a 
density of 1.021 and did not contain proteins, epithelial cells or bacteria. The urine was 
previously centrifuged (10,000 x g, 10 minutes) and filtered through a 0.45 µm-pore-size 
polycarbonate membrane. After 0, 2, 4, 6, 8, 10, 12 hours aliquots of test samples and of 
bacterial and phage controls were collected to quantify bacteria and phages. 
3.8. Statistical analysis 
Statistical analysis was performed using SPSS (SPSS 20.0 for Windows, SPSS 
Inc., USA). Normal distributions were checked by Shapiro-Wilk test. Homogeneity of 
variance was checked by Levene test. The existence of significant differences among the 
different phage therapy conditions was assessed by one-way analysis of variance 
(ANOVA) model. For each situation, the significance of the differences was done by 
comparing the results obtained in the test samples with the results obtained for the 
correspondent control samples for the different times of each of the three independent 
assays. A value of p < 0.05 was considered to be statistically significant. 
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4. Results 
4.1. Phage host range 
The isolated phages on E. cloacae infected bacteria from Salmonella spp., 
Escherichia coli, Proteus, Citrobacter and Shigella flexneri, all members of the 
Enterobacteriaceae family, but no bacteria belonging to the other families tested. Detailed 
results are described in Table 5.  
Table 5 - Bacterial sensitivity to bacteriophages E-2, E-3 and E-4 isolated on E. cloacae. 
Species 
Infectivity of phage 
E-2 E-3 E-4 
Salmonella Typhimurium ATCC 14028 - + + 
S. Typhimurium ATCC13311 - - - 
Salmonella Enteriditis CVA + + + 
S. Enteriditis CVB - - - 
S. Enteriditis CVC - - - 
S. Enteriditis CVD - - - 
S. Enteriditis CVE - + - 
E. coli ATCC 25922 - - - 
E. coli ATCC 13706 - - - 
E. coli BC30 + - + 
E. coli AE11 - - - 
E. coli AD6 - - - 
E. coli AF15 - - - 
E. coli AN19 ++ ++ ++ 
E. coli AC5 - + - 
E. coli AJ23 - + - 
E. coli BN65 - - - 
E. coli BM62 + - - 
Shigella flexneri DSM 4782 ++ ++ ++ 
Citrobacter freundii 6F + - - 
C. freundii 10I + - - 
Providencia sp. - - - 
P. vermicola - - - 
Proteus vulgaris  - - - 
Proteus mirabilis + + - 
K. pneumoniae - - - 
Enterococcus feacalis - - - 
E nterococcus faecium - - - 
S.aureus DSM 25693 - - - 
S. aureus ATCC 6538 - - - 
S. aureus 2065 MA - - - 
S. aureus 2153 MA - - - 
S. aureus 2043 MA - - - 
S. aureus 2043 MA - - - 
Listeria innocua NCTC 11288 - - - 
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L. monocytogenes NCTC 1194 - - - 
Vibrio parahaemolyticus DSM 27657 - - - 
V. anguillarum DSM 21597 - - - 
V. fischeri ATCC 49387 - - - 
Photobacterium damselae damselae DSM 7482 - - - 
Aeromonas hydrophilla ATCC 7966 - - - 
A. salmonicida CECT 894 - - - 
Pseudomonas aeruginosa - - - 
P. fluorescens - - - 
P. putida - - - 
P. segetis - - - 
P. gingeri - - - 
Total number of strains infected 8 8 5 
 
4.2. Phage survival determination 
The results of the survival of E. cloacae phages on PBS are represented in Figure 
4. The concentration of E-2 decreased by two orders of magnitude in the first 105 days. E-
3 concentration decreased by two orders of magnitude in the first 20 days and reached a 
plateau until 77 days. Afterwards, the phage titer decreased by three orders of magnitude 
until 156 days. E-4 concentration only decreased by one order of magnitude after 255 
days (Figure 4). 
 
Figure 4 - Survival of E-2, E-3 and E-4 phages in PBS. Values represent the mean of 
three experiments; error bars represent the standard deviation. 
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4.3. Genome sequencing 
A total of 23955 reads were produced, with 460 bp average read length, resulting 
in a total of 110’342’246 bases. Specifically, 22’256 reads were obtained for E-4, 11’5491 
for E-2 and 31’628 for E-3. Phage genomes were de novo assembled using CLC 
Genomics Workbench 7 and Roche GSAssembler 2.7. Phages E-2 (1’367-fold coverage, 
36’275 bp genome), E-3 (404-fold coverage 31’522 bp genome) and E-4 (235-fold 
coverage, 39’142 bp genome) were assembled with the GSAssember software. 
 
4.4. E. cloacae inactivation in PBS 
 
4.4.1. E. cloacae inactivation by single-phage suspensions 
 E. cloacae was challenged with the three phages, separately and in a cocktail, in 
order to assess their potential as therapeutic agents. The maximum of bacterial 
inactivation with the E-2 phage was 3.4 log after 4 h of incubation and after 12 h was still 
significantly high (1.6 log) relatively to the bacterial control (ANOVA, p < 0.05) (Figure 5A). 
No decrease of the phage survival (ANOVA, p > 0.05) was observed during the 24 h of 
the experiments for the phage controls, however, when the phage was incubated in the 
presence of the host, a significant increase in phage concentration was observed after 24 
h relatively to phage control (1.1 log) (ANOVA, p < 0.05) (Figure 5B). 
 When the E-3 phage was tested, a maximum bacterium inactivation was observed 
after 4 h (3.8 log) and after 12 h the rate of inactivation was still significantly high (2.3 log) 
relatively to the bacterial control (ANOVA, p < 0.05) (Figure 5A). A significant increase of 
1.2 log in phage concentration was observed after 24 h relatively to phage control 
(ANOVA, p < 0.05). Phage control remained constant during the treatment from the 
beginning of the treatment (ANOVA, p > 0.05) increasing significantly, 1.2 log, in the 
presence of the host after 24 h (ANOVA, p < 0.05) (Figure 5B). 
 The maximum of bacterium inactivation by the E-4 phage was 3.8 log after 6 h 
(ANOVA, p < 0.05) relatively to the bacterial control. After 12 h the bacterium inactivation 
was still high (2.5 log) relatively to the bacterial control (ANOVA, p < 0.05) (Figure 5A). 
The phage control remained constant since the beginning of the treatment (ANOVA, p > 
0.05), but the phage concentration increased considerably in the presence of the host, by 
1.8 log, (ANOVA, p < 0.05) (Figure 5B). 
Phages E-2 and E-3 inactivation was similar during the treatment (ANOVA, p > 
0.05). Compared to phage E-2 and phage E-3 the inactivation of the bacteria by the  
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phage E-4 was less efficient until 4 h of treatment but after 6 h it was significantly 
more efficient than the other phages inactivation (ANOVA, p < 0.05) (Figure 5A).  
 
4.4.2. E. Cloacae inactivation by phage cocktails 
 When the E-2/E-4 phage cocktail was used, the maximum of bacterial inactivation 
was 4.3 log after 4 h of incubation. After 12 h the inactivation was 3.6 log. These results 
are significantly different from the values obtained for the phages E-2 and E-4 alone 
(ANOVA, p < 0.05) (Figure 6A). No decrease in the phages survival was observed during 
study period (ANOVA, p > 0.05) but in the presence of its host phage cocktail 
concentration increased significantly (ANOVA, p < 0.05) (Figure 6B) by 1 log. 
  
 
B 
A 
Figure 5 - Inactivation of E. cloacae by the three phages (E-2, E-3 and E-4) at a MOI of 100 
during the 24 h. (A) Bacterial concentration: BC – Bacteria control; B+P – Bacteria plus phage. 
(B) Phage concentration: PC – phage control; B+P – Bacteria plus phage. Values represent the 
mean of three experiments; error bars represent the standard deviation. 
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With the phage cocktail E-2/E-3 was tested, the maximum of bacterial inactivation 
was 3.7 and 3.5 log, respectively after 4 h and 12 h of incubation. The inactivation was 
significantly higher from the value obtained when phage E-2 was used alone (ANOVA, p < 
0.05). However, when compared to E-3 inactivation the results were not significantly 
different (ANOVA, p > 0.05) (Figure 6A). No decrease in the phages survival was 
observed during study period (ANOVA, p > 0.05) and in the presence of its host the phage 
concentration increased significantly (ANOVA, p < 0.05) by 1 log (Figure 6B). 
Using the phage cocktail E-3/E-4 the maximum rate of the bacterial inactivation 
occurred within 4 h of incubation and was about 3 log. After 12 h of incubation the 
inactivation rate was 1.3 log. These results were significantly different from results 
obtained in the assays with both phages separately (ANOVA, p < 0.05) (Figure 6A). The 
phages survival during the study period was constant (ANOVA, p > 0.05) and there was 
an increasing in phage concentration in the presence of the host during the study time 
(ANOVA, p < 0.05) of 1.3 log (Figure 6B). 
With the phage cocktail E-2/E-3/E-4 the maximum of bacterial inactivation was 3.5 
log achieved after 4 h of incubation and of 1 log after 12 h. These results are significantly 
different from the results obtained using E-3 and E-4 alone (ANOVA, p < 0.05), but are 
similar with the results obtained using E-2 phage (ANOVA, p > 0.05) (Figure 6A). The 
phages survival was constant during the study period (ANOVA, p > 0.05) and an increase 
of 1 log in phage concentration in the presence of bacterial host was observed (ANOVA, p 
< 0.05) (Figure 6B). 
The inactivation of the bacteria by the phage cocktails E-2/E3, E-2/E-4 and E-2/E-
3/E-4 was similar (ANOVA, p > 0.05) but the phage cocktail E-3/E-4 was less effective 
than the other 3 to inactivate the bacteria (ANOVA, p < 0.05) (Figure 6A).  
A 
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4.5. E. Cloacae inactivation in Urine 
We wanted to assess the properties of the phages in question in the clinically 
relevant setting, therefore the killing assays were repeated in urine. The best results were 
obtained with phage cocktail E-2/E-4. The maximum bacterial inactivation was 2 log 4 h 
after the beginning of treatment. These results are significantly different from the results 
obtained in phage therapy in PBS (ANOVA, p < 0.05) (Figure 7A). The phage survival was 
constant during the 24 h of treatment (ANOVA, p > 0.05) and increase significantly, by 1 
log, in the presence of the host (Figure 7B).  
The maximum bacterial inactivation for E-2 in urine samples was 2 log after 4 h of 
treatment, these results are significantly different from those obtained in PBS (ANOVA, p 
< 0.05) (Figure 7A). The phage survival was constant during study period (ANOVA, p > 
0.05), and increased significantly (1 log) in the presence of the host after 12 h of treatment 
(ANOVA, p < 0.05) (Figure 7B). The bacteria inactivation by the phage E-4 was 
significantly lower compared to the results obtained using the phage cocktail E-2/E-4 and 
the E-2 phage in urine (1 log after 4 hours) (ANOVA, p < 0.05) (Figure 7A). The phage 
survival was constant during the experiments (ANOVA, p < 0.05) and phage concentration 
increased significantly in the presence of the host bacteria (ANOVA, p < 0.05) (Figure 7B).  
B 
Figure 6 - Inactivation of E. cloacae by phage cockails (E-3/E-4, E2/E3, E2/E4 and E2/E3/E4) at a 
MOI of 100 during the 24 h. A Bacterial concentration: BC – Bacteria control; B+P – Bacteria plus 
phage .B Phage concentration: PC – phage control; B+P – Bacteria plus phage. Values represent the 
mean of three esperiments; error bars represent the standard deviation. 
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The inactivation of the bacteria in urine samples by the phage cocktail E-2/E4 and 
phage E-2 was similar (ANOVA, p > 0.05) but the phage E-4 was less effective than the 
cocktail and the phage E-2 (ANOVA, p < 0.05) (Figure 7A). 
 
 
 
 
 
 
 
A 
B 
Figure 7 - Inactivation of E. cloacae by phage E-2 and E-4 and the cocktail E2/E4 in urine at a MOI of 
100 during the 12 h. (A) bacterial concentration: BC – Bacteria control; B+P – Bacteria plus phage. (B) 
Phage concentration: PC – phage control; B+P – Bacteria plus phage. Values represent the mean of the 
three experiments; error bars represent the standard deviation 
  
 
37 
 
5. Discussion 
The emergence of antibiotic resistant bacteria directed more research interest to 
alternative therapies. Several studies have demonstrated that phage therapy has great 
potential in the inactivation of infections caused by bacteria. The E. cloacae infection has 
major importance to be a cause of urinary tract infections difficult to control (Zhanel, 
Hisanaga et al. 2005). There is not yet any report on the application of phage therapy in E. 
cloacae. 
The biggest challenge of phage therapy is the selection of suitable phages, that 
besides are not temperate and have broad activity and long survival in the environment, 
do not carry toxin genes and do not perform generalized transduction. Therefore, it is 
mandatory to perform whole genome sequencing and assesses specific properties of the 
phage. The genome sequence of the three phages isolated in this study did not detect the 
presence of genes encoding toxins, antibiotic resistance and integrase enzymes. 
Consequently, these phages can be considered safe to be used in phage therapy. 
Other concern of this therapy is the emergence of phage resistant bacteria (Levin 
and Bull 2004, Vieira, Silva et al. 2012). However, resistance to phage can be overcome 
by the phage itself because it evolves together with the host and this aspect is one of the 
major advantages of a phage over the “static” antibiotic. Moreover, the use of phage 
cocktails has managed to overcome this problem (Zhang, Kraft et al. 2010, Chan and 
Abedon 2012, Chan, Abedon et al. 2013). In fact, the use of phage cocktails has been 
indicated as a good alternative for the treatment of bacterial infections. Since the 
beginnings of phage therapy use in the Eastern countries this approach has been 
preferred. However, one must keep into account that the more phages used in treatment, 
the higher the probability of non-specific infections to occur. Less complex cocktails, for 
example, two to ten distinct phages, are the best option (Chan, Abedon et al. 2013). 
With the exception of the cocktail E-3/E-4, the phage cocktails of 2 and 3 phages 
presented a significant increase in the inactivation of bacteria compared to the use of 
isolated phages. These results can be explained by a delay in the development of phage 
bacterial resistance. Between 4 and 10 h of incubation, the increase in the bacterial 
concentration was of ≈ 3 log when phage cocktails were used but of ≈ 4 log when the 
single phage suspensions were tested. As the efficacy of bacterial inactivation by the 
three phages has been similar when they were used alone, the phages of cocktails E-2/E-
3, E-2/E-4 and E-2/E-3/E-4 probably used different bacterial receptors to adsorb to E. 
cloacae and, consequently, the time necessary to develop resistance to the two or three 
phages is higher. However, the phages E-3 and E-4 probably used the same receptor to 
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infect E. cloacae. For the selection of phage cocktails it is important to consider the 
receptors used by the phage to infect the host to improve bacterial inactivation 
effectiveness and to limit the development of resistance (Filippov, Sergueev et al. 2011). 
Although in all treatments the used phages were unable to control the host, after 
treatment some bacteria survive to the phage infection, probably due to phage resistance 
development by the host. However, the rate of inactivation achieved after 4 h of treatment, 
only two log of bacteria survive, can be enough to allow the immune system of the 
infected person to control the infection. Moreover, previous studies suggest that phage 
resistant bacteria tend to be less fit or lose their virulence properties (Wagner and Waldor 
2002, Filippov, Sergueev et al. 2011). 
The phage cocktail E-2/E-4 was effective to inactivate E. cloacae in human urine. 
However, although the phages of the cocktail E-2/E-4 survived in the urine, maintained 
their concentration in the absence of the host and significantly increased their titer in the 
presence of the bacterium during the study period, its effectiveness to inactivate the E. 
cloacae in urine was considerably lower compared to that observed in the experiment in 
PBS, 2.0 log against to 4.3 log after 4 h, respectively. Considering the results of bacterial 
inactivation in urine using the single suspensions of both phages it is clear that the 
decrease in the bacterial inactivation, relatively to the inactivation in PBS, was mainly due 
to phage E-4. The inactivation of the bacteria in urine samples by the phage E-4 was only 
of 1 log. The inactivation by the phage E-2 was of 2 log, similar to that observed with the 
phage cocktail in urine samples and 2 log lower that the inactivation with the same 
cocktail in PBS. As the phages maintain their stability during the incubation period in 
urine, and replicate in the presence of the host as well as in the PSB, the lower bacterial 
inactivation in urine seems not to be due to a lower phage replication of the phages. It has 
been shown that although phages survive in different values of pH, temperature, salt 
concentration, organic matter concentration, the efficiency of phage therapy is significantly 
affected by salt concentration and organic matter concentration (Silva et al., 2014). The 
increase in salt concentration and organic matter concentration increased the efficiency of 
phage therapy against Vibrio parahaemolyticus (Silva et al., 2014). As organic matter 
concentration in the human urine is higher than in the PBS and the salt concentration is 
lower in human urine (≈ 3 g L-1) than in PBS (9 g L-1), the lower efficiency of phage 
therapy in urine at a first glance, seems to be due to the lower values of salt. However, 
other studies have shown that the interplay between receptor-binding protein and cellular 
ligand is strongly dependent on Ca-ions and other salts (Binetti, Quiberoni et al. 2002, 
Harada, Yamashita et al. 2013). High salt concentrations can lead to unspecific binding 
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which is not followed by infection (Silva, Costa et al. 2013). However, in this study, the 
phage concentration increased significantly in the presence of the bacterium during the 
study period in urine. Further studies to determine the exact receptors and their binding 
protein are needed. 
The results of this study show that the three phages can inactivate pathogenic 
bacteria from different genera of the family Enterobacteriacea, most of them also 
implicated frequently in UTI, which suggest that these phages can be used to inactivate 
these uropathogens. These three phages do not infect bacteria belonging to other 
families. The phage E-2 presented the broader host range for the Enterobacteriaceae 
strains, infecting 5 genera and the phage E-4 the smaller host range, infecting 3 genera. 
However, the E-4 phage was as effective as the other two to inactivate the E. cloacae and 
when this phage was used in combination with the broader host range E-2 phage, the rate 
of inactivation reached a higher value and a lower value of resistant bacteria proliferation. 
The results suggest that the combination of an effective phage with other, with a broader 
host range can be a practical approach to treat UTI caused by Enterobacteriaceae. 
The results of this study showed that the three phages can survive in the buffer 
solution during several months (6 - 8) and in urine, at least 12 h, replicating efficiently in 
the presence of the pathogenic bacteria. Unlike antibiotics, phages are self-replicating as 
well as self–limiting, and, consequently, they replicate exponentially as bacteria replicate 
and decline when bacterial numbers decrease (Almeida et al., 2009). In this study it was 
possible to produce phages suspensions with high titers, up to 1010 PFU mL-1, suitable to 
use in phage therapy, that declined when bacteria were removed, but maintaining their 
high concentrations. 
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Chapter 3 – Introduction 
 
The Hepatitis caused by viruses presents a great importance due to its worldwide 
distribution, reaching pandemic proportions. The Hepatitis A virus (HAV), Hepatitis B virus 
(HBV), Hepatitis C virus (HCV), Hepatitis D virus (HDV), Hepatitis E virus (HEV) and 
Hepatitis G virus (HGV) are biologically distinct although they all have in common the 
destruction of hepatic tissue (Araújo, Mendonça et al. 2007).  
1. Hepatitis A 
Hepatitis A first written account, according to a review by Cockayne (1912), was 
the description of an epidemic on the island of Minorca in the 18th century. Subsequently, 
many other reports of epidemics were made, and the name of catarrhal jaundice was 
given by Virchow due to the amount of bile thrombi observed from the autopsies 
(Cockayne 1912). The suspicion that the cause of the disease could be viral only emerged 
in 1931 by Findlay and Cols (Findlay 1932). 
Hepatitis A virus (HAV) belongs to the Hepatovirus genus within the Picornaviridae 
family. It is a nonenveloped single-stranded RNA virus and has an icosahedral capsid of 
30 nm (Feinstone, Kapikian et al. 1973). HAV replicates in hepatocytes and sparks an 
immune response causing liver inflammation. There is genetic variability between HAV 
isolates from different parts of the world and it is possible to classify HAV strains into 6 
genotypes. Genotypes I to III are found in humans and genotypes IV to VI are found in 
simians. The phenotype I is the most common, being found in 80% of the infected people 
(Robertson, Jansen et al. 1992). 
HAV causes acute liver disease worldwide, formerly known as infectious hepatitis, 
being annually estimated 1.4 million cases of new infections (Bell, Shapiro et al. 1998). 
Despite the low mortality rate (between 0.1% and 2.1%), it causes a very significant 
morbidity. Symptoms include in average a week of gastrointestinal and flulike symptoms, 
anorexia and dark urine; several weeks of jaundice, and then it follows a period of several 
weeks of convalescence (Cuthbert 2001). HAV may also lead to extrahepatic 
complications (e.g. pancreatitis, vasculitis and glomerulonephritis). The main cause of 
death is fulminant hepatitis associated to chronic liver disease (Ciocca 2000). Hepatitis A 
causes epidemic waves that are usually repeated at intervals varying in accordance with 
the virus circulation (Rosenthal 2003). 
Hepatitis A is transmitted by fecal-oral route, either by direct contact with an HAV-
infected person or by ingestion of HAV-contaminated food or water. As the period of 
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viremia is short and the concentration of virus in the blood is low, transmission by blood or 
contaminated material is rare, but it can occur if the injected material (serum or blood) 
have been derived from an individual in incubation period. Sporadic cases have been 
reported after blood transfusions. The infection rate is strongly correlated with sanitary 
conditions but also with the educational level indicators, food preparation by contaminated 
handlers and consume of contaminated shellfish grown in polluted water (Hutin, Pool et al. 
1999, Staes, Schlenker et al. 2000, Shepard, Simard et al. 2006). There are also high-risk 
groups, including drug addicts, day-care employees and homosexuals due to the high 
promiscuity and the oro-anal practices (Desenclos and MacLafferty 1993). The risk of 
exposure is higher in military personnel then in civil community due to communal living 
standards, and also due to the fact that militaries are often recruited to high endemic 
areas (Hutin, Pool et al. 1999). For people susceptible to HAV, it is estimated that the risk 
of contracting the disease travelling to developing countries is 3 to 6 cases per 1000 
travellers per month but in case of “backpacking” travellers and humanitarian action 
volunteers, the risk is 20 cases per 1000 travellers (Shepard, Simard et al. 2006). 
There are three phases included on the course of the disease: incubation, 
symptomatic infection and convalescence. HAV fecal excretion occurs from the incubation 
to early symptomatic phase. The incubation period range from 15 to 50 days and the peak 
of infectivity occurs as serum alanine aminotransferase concentration increases (Bower, 
Nainan et al. 2000). The main serological marker, IgM anti-HAV, can be detected between 
5 days and 6 months after exposure. IgG anti-HAV confers lifelong immunity, this antibody 
can also be detectable in the symptomatic phase (CDC 1999, Wasley, Samandari et al. 
2005). (Figure 8). 
 
 
 
 
 
 
Figure 8 - Events that occur during HAV infection (adapted from 
Paula et al 2012). 
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Hepatitis A generally has a good prognosis. Mortality is shown to be very low in 
young, increasing if the disease is acquired from the fourth decade of life (Kemmer and 
Miskovsky 2000). 
2. Hepatitis C 
Hepatitis C has been studied for decades, even before the discovery of the agent 
responsible for the disease, the hepatitis C virus (HCV) (Houghton 2009). In 1970, 
serological screening tests to investigate the HAV and HBV, showed that 25% of cases of 
hepatitis associated with blood transfusions were associated with HBV. The remaining 
75% were considered as hepatitis non-A and non-B (NANB) (Araújo, Mendonça et al. 
2007). Only after observation of some cases of NANB hepatitis that progressed with 
elevated alanine aminotransferase (ALT) and cirrhosis, came a greater interest in studying 
a potential responsible of this "new disease" (Alter 1999). 
HCV is a small linear RNA virus (50-60 nm) with a single filament classified in the 
Flaviviridae family and Hepacivirus genus, being transmitted through the bloodstream 
(Walsh and Alexander 2001, Noorali, Pace et al. 2010). It has half-life of 2.7 hours and 
preliminary data suggest that HCV is able to penetrate the hepatocyte through CD81 
receptor site where it replicates preferentially (McHutchison 2004). It has a very high rate 
of replication (1012 virions per day). HCV does not replicate via a DNA intermediate nor 
interact within the genome of the host, i.e. is not cytopathogenic (Malkevich, Womack et 
al. 2001). 
In developed countries, before the introduction of routine testing of donated blood, 
the HCV main course of transmission were blood and blood products transfusions. 
Nowadays the illicit use of injectable drugs is the main source of HCV transmission. The 
prevalence of HCV in drug users is higher than that of human immunodeficiency virus 
(HIV) (Champion, Taylor et al. 2004). In developing countries the use of re-used and non-
sterilized syringes and needles in medical procedures is the main cause of transmission. 
Sexual transmission is less common than with Hepatitis B virus (HBV) and the risk of 
perinatal transmission is low (Noorali, Pace et al. 2010). 
The main serological marker is anti-HCV, the presence of anti-HCV antibodies 
cannot be confirmed until 12-27 weeks after exposure, creating a window period of 
seronegativity and elevated risks of infectivity. In cases where the anti-HCV antibody is 
positive the quantification of viral RNA, the HCV core antigen EIA and the genotype 
screening are indicated tests (Mast, Alter et al. 1999). Apart from the 
detection/quantification of the genome, determination of viral genotype is highly relevant in 
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clinical practice, particularly in the selection of therapy, defining the duration of treatment 
and dosage adjustment of antivirals (Anjo, Café et al. 2014).  
In Portugal, the combination of Pegylated interferon alpha (PEG IFN- α) and 
ribavirin (RBV) therapy is approved for the treatment of chronic HCV infection in 
individuals with HCV infection of non-1 genotypes (Anjo et al., 2014; Saludes et al., 2014). 
This combination therapy provides healing in approximately 60% of patients (Velosa, 
Caldeira et al. 2012), however has several serious side effects such as anemia, 
granulocytopenia, and depression, and is associated with long-term treatment and high 
cost. The effectiveness of the combined PEG IFN-α and RBV therapy is less than 50% for 
genotype 1 HCV, the most prevalent genotype (Lok, Gardiner et al. 2012). 
The acute hepatitis C is commonly asymptomatic. When symptomatic, it includes 
anorexia, vague abdominal discomfort, nausea and vomiting, fever and fatigue, 
progressing to jaundice in about 25% of patients (Marcellin 1999). Eventually, 60% - 90% 
of infected people evolve to chronic disease. Chronic hepatitis is defined as a continuing 
disease without improvement for at least six months (Dubuisson, Hsu et al. 1994). 
HCV infection is associated with a wide spectrum of liver damage, which can 
range from minimal histological changes to liver cirrhosis, hepatocellular carcinoma or 
eventually death (Veldt, Heathcote et al. 2007). Fulminant hepatitis is rare, except in co-
infection with hepatitis A. The development of cirrhosis is age-dependent and the risk is 
higher when the infection occurs after 40 years old. Approximately 20% of those who 
develop cirrhosis will suffer hepatocellular carcinoma (Maasoumy and Wedemeyer 2012) 
(Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 - Natural history of Hepatitis C virus infection (Maasoumy and 
Wedemeyer, 2012) 
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There are seven drugs licensed for the treatment of HCV – standard interferon 
(IFN) or pegylated interferon alpha (PEG-IFN), ribavirin (RBV), the protease inhibitors 
(PIs) boceprevir, simeprevir and telaprevir, the nucleotide analog polymerase inhibitor 
sofosbuvir and the most recently licensed treatment ABT-450/r–Ombitasvir and Dasabuvir 
with Ribavirin. The seventh is the most effective treatment with a sustained virologic 
response in 90% of cases. The limitations of HCV treatment include high cost, the need 
for sophisticated laboratory tests and trained clinicians, as well as the limited efficacy and 
high toxicity of most of the medicines (WHO 2014). To administer the appropriate 
treatment is important to determine the genotype of the virus (Velosa et al., 2012). 
The public health importance of these two forms of hepatitis are increasingly being 
recognized. This study aims to evaluate the variation in prevalence of hepatitis A and 
hepatitis C in the district of Aveiro, in the period of 2002 to 2012, in order to broaden the 
knowledge of epidemiology of these diseases in Portugal and prevent spreading and 
future outbreaks.  
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1. Abstract  
Hepatitis A is a common viral liver disease and brings serious health and 
economic problems as its epidemiologic pattern changes over time. National serosurveys 
from developed countries have indicated a decline in HAV (hepatitis A virus) seroprevalence 
over time due to the improvement of economic and sanitation levels. The hepatitis A virus 
(HAV) immunity rate was surveyed throughout an eleven-year period by sex and age 
group in Aveiro District. In this retrospective study, blood samples from patients of Aveiro 
District, in ambulatory regime, collected at the Clinical Analysis Laboratory Avelab 
between 2002 and 2012 were screened for the presence of antibodies against HAV 
antigen using a chemiluminescence immunoassay. The global immunity (positive total 
anti-HAV) was 60% and only 0.3% of the patients presented recent infection by HAV 
(positive IgM anti-HAV). The HAV immunity was age-dependent (p < 0.05), but no 
significant differences (p > 0.05) between sexes were observed. The immunity was similar 
throughout the study period (p > 0.05). The results of this study indicate that young people 
(especially under 25 years old) from District of Aveiro are susceptible to HAV infection, 
constituting a high risk group. The elderly should be also a concern in the future of 
Hepatitis A infection. 
Keywords: Hepatitis A; immunity; surveillance study; epidemiology; Portugal 
2. Introduction 
Hepatitis A is an acute disease transmitted by fecal-oral route, either by direct 
contact with an HAV-infected person or by ingestion of HAV-contaminated food or water. 
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During the course of the disease there are three phases: incubation, symptomatic 
infection and convalescence and the HAV excretion occurs from the incubation to early 
symptomatic phase. The incubation period ranges from 15 to 50 days (Feinstone, 
Kapikian et al. 1973). The main serological marker, IgM anti-HAV can be detected 
between five days and 6 months after exposure. Anti-HAV IgG confers lifelong immunity 
and this antibody can also be detectable in the symptomatic phase (Lemon, Jansen et al. 
1992, Robertson, Jansen et al. 1992). 
HAV causes liver disease worldwide, being annually estimated 1.4 million cases of 
new infections (Bower, Nainan et al. 2000). Despite the low mortality rate (between 0.1% 
and 2.1%), it causes a very significant morbidity (Wasley, Samandari et al. 2005). HAV 
may also lead to extrahepatic complications (e.g., pancreatitis, vasculitis and 
glomerulonephritis). The main cause of death is fulminant hepatitis associated to chronic 
liver disease (CDC, 1999). Hepatitis A causes epidemic waves that are usually repeated at 
intervals varying in accordance with the virus circulation (Bell, Shapiro et al. 1998). 
In developed countries, the HAV incidence has declined essentially due to the 
great improvements of sanitary conditions (Rosenthal 2003). However, a decrease of 
immune individuals leads to an increased risk of potential outbreaks. In such 
circumstances, these outbreaks may be unpredictable and difficult to control. This concern 
is also focused on the fact that, in children, hepatitis A is mostly asymptomatic. In adults, 
70%–89% of cases are symptomatic and with increasing age the symptoms are 
worsened. Thus, although the incidence in population has decreased, there is an increase 
in costs per case of HAV infection as a large segment of the population is now susceptible 
to it (Luyten and Beutels 2009). There is an evidence that many of the outbreaks are 
misdiagnosed (FitzSimons, Hendrickx et al. 2010). According to the World Health 
Organization (WHO), annual reports show about 100,000 cases of outbreaks in Europe, 
500 of them being fatal. Knowledge of anti-HAV seroprevalence rates in the world and in 
each region of a country is of utmost importance to establish public health priorities and to 
adopt adequate vaccination policies (WHO, 2009). 
In 2011, the WHO has compiled the immunity studies made across the world and 
a summary was made. In western countries, the overall immunity was 50%, and less than 
20% to people aged less than 20 years. In this region, in which Portugal is included, there 
is a low child immunity rate and the adult susceptibility rate is high. In Central and Eastern 
Europe, there is a low-medium child immunity rate and the adult susceptibility rate is 
medium. In North America, there is a low child immunity rate and medium susceptibility in 
adults (WHO, 2009). Between 1996 and 2006, 1164 patients were hospitalized with HAV 
  
 
55 
 
in Portugal, 30% were younger than 15 years and 3% had severe liver failure (data of the 
Computing and Financial Management of Health) (Marinho, Valente et al. 2000). 
According to the largest epidemiological survey carried out in Portugal in 1984, comprising 
1770 individuals distributed among several districts, the immunity rate for the Portuguese 
population was 84.9% and 93.4% to people aged less than 20 years. This country was 
considered highly endemic (Lecour, Ribeiro et al. 1984). 
The vaccine is highly immunogenic, conferring protection against HAV in 
approximately 95% of the vaccinated patients (Rosenthal 2003). Protection is considered to 
be lifelong after a complete hepatitis A vaccination schedule (two doses) (Landry, Tremblay 
et al. 2000, Raczniak, Thomas et al. 2013). A combined hepatitis A/B vaccine with high 
immunogenicity is also available in some countries (Kallinowski, Knöll et al. 2000). The 
vaccine is not yet widely used but in more developed countries it is recommended for risk 
groups. Moreover, some studies have found that universal vaccination is cost-effective 
(Jacobs, Margolis et al. 2000, MacIntyre, Burgess et al. 2003, Rosenthal 2003, Bauch, 
Anonychuk et al. 2007). In Catalonia, the universal vaccination program of preadolescents 
began in 1998 and has avoided 90% of cases in young people aged 12–19 years (Navas, 
Salleras et al. 2005). In Portugal, the vaccine has been available since 1998 but is not yet 
widely used, and it is only recommended for specific at-risk groups. According to the 
national health regulatory authority (DGS) recommendations, children, adolescents or 
adults who travel to high or intermediate endemic countries, adolescents and adults with 
chronic liver disease or who belong to a community where an outbreak is detected should 
be primarily vaccinated (Cavaco, 2010). The vaccine is not yet included in the National 
Plan of Vaccination (DGS, 2012). 
The public health importance of this form of hepatitis is becoming increasingly 
recognized as the epidemiological picture of the disease has been dramatically changing 
in recent years. In many countries, outdated data are still being used in policy decisions 
(FitzSimons, Hendrickx et al. 2010). Seroprevalence studies of hepatitis A as well as the 
evaluation of the cost-benefit of the vaccine may contribute to the decision of extending 
vaccination to the entire population. This study aims to evaluate the prevalence of 
hepatitis A in Aveiro District, from 2002 to 2012, in order to broaden knowledge on the 
epidemiology of this disease in Portugal and to assess the risk of outbreaks of HAV. 
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3. Material and Methods 
3.1. Samples 
In this retrospective study all serum samples analysed for total anti-HAV and IgM 
anti-HAV from patients of the District of Aveiro, in ambulatory regime, collected at the 
Clinical Analysis Laboratory Avelab (Aveiro, Portugal) during the period 2002-2012, were 
analysed. The Clinical Analysis Laboratory Avelab comprises delegations located in 14 
municipalities in the district of Aveiro and Coimbra. 
A total of 7894 samples (4357 from male and 3537 from female) were collected 
during the study period. All patients were grouped by age ranges: 0-5, 6-15, 16-25, 26-35, 
36-45, 46-55, 56-65 and >66. 
The age and sex of each patient were registered.  The vaccination history of the 
patients was not considered. The study was approved by the Ethical Committee of  the 
Clinical Analysis Laboratory Avelab, specifically by the Pharmacist Dr. António Ferreira 
Neves and Doctors Alberto Ferreira Neves, António Rodrigues and Maria Teresa Raposo. 
3.2. Sampling 
Samples were collected, using the Avelab Laboratory protocol. The venous blood 
of the patients was collected and reserved into a tube with separator spheres allowing clot 
formation. The samples were centrifuged at 1381 x g for 10 minutes. The blood samples 
were analyzed within one hour after collection. When this procedure was not possible the 
samples were stored at 2-8ºC and processed until 24 hours after collection. The samples 
were dismissed 7 days after sampling. 
3.3. Antibodies Detection 
The samples were analyzed in an automated Siemens ADVIA Centaur® XP 
immunoassay analyzer. It was used the acridinium ester (AE) as the chemiluminescent 
label. Samples were diluted in buffer and purified HAV antigen was added forming in the 
presence of specific antibodies (IgG and/or IgM) immune complexes. AE labeled mouse 
monoclonal anti-HAV antibodies, biotinylated mouse monoclonal anti-HAV Fab fragment 
and streptavidin coated paramagnetic capture particles were incubated with the immune 
complexes. The biotinylated conjugate and acridinium labeled conjugate bind to antigen 
sites not occupied by sample HAV antibodies. A magnet is used to separate the 
microparticles and the unbound material is washed. The bound acridinium ester conjugate 
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is then measured by a chemiluminescent reaction. The amount of light produced is 
inversely proportional to the antibodies concentration (Siemens, 2006). 
Total anti-HAV and/ or IgM anti-HAV were analyzed in all samples. The presence 
of IgM anti-HAV indicates recently infected patients and the presence of total anti-HAV 
(IgG anti-HAV and IgM anti-HAV) indicates that patients had previous or ongoing 
infection. The samples were classified as non-infected, recently infected, immune and 
non-immune, according to the detected antibodies. The patients were classified as 
immune when the result of total anti-HAV was positive and infected when the result of IgM 
anti-HAV was positive. Patients with negative anti-HAV antibodies (negative total anti-
HAV and negative IgM anti-HAV) were considered non-immune and patients with negative 
IgM anti-HAV were considered non-infected. 
3.4 Statistical analysis 
The data were treated using the Statistical Package for the Social Sciences 
(SPSS) 20.0 for Windows. To simplify the statistical analysis the patients were grouped by 
age ranges: 0-5, 6-15, 16-25, 26-35, 36-45, 46-55, 56-65 and >66. The absolute (n) and 
relative (%) frequencies were presented for qualitative variables. The normality of data 
was checked before analysis. As all the variables failed this statistical method assumption, 
the non-parametric Chi-square (X2) test was used to check if the distribution of variables 
was similar in the different groups for immunity. The significance level established was 
0.05. 
4. Results 
4.1. Hepatitis A 
4.1.1. Characterization of the sample 
The annual average of analyzed samples was 718. It was observed a decrease of 
about 7% on the number of analysis performed between 2009 and 2012 (Fig.10-A). From 
the total of 7894 serum samples analyzed between 2002 and 2012, 4357 (55.2%) were 
performed in male patients and 3537 (44.8%) in females. The age of the patients ranged 
between 0 and 99 years. The patients aged between 26-35 years represented the age 
group that carried out more analysis. In general, an increase of the percentage of analysis 
performed until the age of 26-35 years was observed, meanwhile a decrease was found 
for patients aged more than 35 years (Fig.10-B). 
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From the 7894 serum samples analyzed, more than half of the patients (60.4%) had HAV 
immunity and only 0.3% of patients were recently infected with HAV (Fig.11). About 30% 
of the patients did not showed immunity against HAV.  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.2. Characterization of HAV immune patients 
There was an abrupt decrease on immunity from 2009 to 2012 but an inversion in 
the ratio of analysis required was also observed. Having into account both analyses (IgM 
anti-HAV and total anti-HAV), the percentage of immunity was 73% (n=966) in 2002, 63% 
(n=953) in 2009 and 28.6% (n=374) in 2012. However, for total anti-HAV detection, the 
percentage of immunity in 2002 was 73.6% (n=954), in 2009 65.2% (n=922) and in 2012, 
67.7% (n=158). Throughout the study period, slight changes in the incidence of the overall 
immunity were observed, but considering only the results of total anti-HAV the percentage 
of immunity did not vary significantly (p>0.05) (Figure 12A). 
The overall immunity was not significantly different between female and male 
patients (p>0.05). However, significant differences in seroprevalence among the different 
age groups were observed (p<0.05). The age of the immune patients ranged from 0 to 99 
Figure 10 - Frequency (%) of the samples by year (A) and age group (B) during the study period. 
Figure 11 - Sample classification during the 
study period. 
B A 
  
 
59 
 
years old with a mean age of 42 years old. With the exception of patients aged less than 5 
years, there was an overall increase of immunity with age. A gradually increase (54.8%) of 
immunity in patients with age comprised between 6 -15 years and between 56-65 years 
was observed, in spite of a decrease of immunity of about 5% in patients aged between 
56-65 and with more than 66 years. For patients aged over 25 years, the percentage of 
immunity was higher than 50% (Figure 12B). 
 
 
 
 
 
 
 
 
 
 
 
4.1.3. Characterization of infected patients 
The age of infected patients with positive IgM anti-HAV ranged from 22 to 87 
years, with a mean age of 44 years. The IgM anti-HAV was detected in 22 patients (8 
males and 12 females). The higher incidence of HAV infection was observed in patients 
aged from 36 to 45 years. The incidence of infection was not significantly different among 
age groups neither between genres (p>0.05) (Figure 13A), but varied over the study 
period (Figure 13B). 
 
 
 
 
 
 
A B 
Figure 12 - Percentage of immune patients by year (A) Percentage of immune patients by 
genre and age group. M – Male; F – Female (B). 
Figure 13 - Number of infected patients by gender and age group (A). Number of infected 
patients by year (B). 
A B 
A B 
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5. Discussion 
When the statistical analysis was made for both analyses (IgM anti-HAV and total 
anti-HAV), the percentage of immunity was 73% (n=966) in 2002, 63% (n=953) in 2009 
and 28.6% (n=374) in 2012. Since 2010, the number of analyzed samples decreased 
abruptly, and on the other hand, at this time a change in the analyses required was 
observed. Before 2010 more than 90% of the analyses were done for total anti-HAV and 
after that there was a big decrease on the number of samples analysed for the total anti-
HAV (in 2012 only 42% of the samples were analysed for the total anti-HAV). This 
changing led to a doubtful result, since IgM anti-HAV does not allow us to survey the 
actual number of immune patients. Considering only total anti-HAV detection to evaluate 
the immunity, about 73.6% (n=954) of the population was found immune in 2002, 65.2% 
(n=922), in 2009 and 67.7% (n=158) in 2012, which indicate that no significant changes 
on immunity rate during the study period was observed in the District of Aveiro. 
In 1984, according to Lacour et. al., 84.9% of the Portuguese population was 
immune to HAV and the prevalence of anti-HAV antibodies in patients aged less than 20 
years old was 93.4% (Lecour, Ribeiro et al. 1984). In 2002, the immunity had decreased 
to 58%, being 62.4% in patients less than 20 years old (Rodrigues, 2004). In Aveiro 
District, the immunity rate was 22.1% for patients aged 6 to 15 years old and 37.2% for 
patients aged 16 to 25 years old. There was a great decrease in prevalence of anti-HAV 
antibodies throughout the last years for these age groups. According to World Health 
Organization (WHO), the estimated immunity rate in western Europe countries was 18% 
for 10-14 age group and 28% for 15-19 age group, values that are even lower than those 
observed in Aveiro District (WHO, 2009). The decrease in the immunity rate for the young 
patients can be explained by the improvement of sanitary conditions in developed 
countries.  
Although, the rate of immunity increased with age, for the children groups the 
immunity was low, bellow 25%, which could lead to an increased risk of unpredictable 
outbreaks in the future (Lednar 1985). It is important to note that for children less than 5 
years old the seroprevalence was higher than for the older children, this can be explained 
by a high number of vaccinated children relatively to the other groups, despite the HAV 
vaccine is not included in National Plan of Vaccination (DGS, 2012). For the elderly 
people (>66) the immunity was lower than that observed for people aged 55 to 66 years 
old, this can be explained by the gradual weakening of the immune system with age. In 
fact, unlike other forms of hepatitis, hepatitis A does not progress to a chronic disease, but 
an association between mortality and age has been observed. A mortality rate of 
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symptomatic disease of 1.5/1000 between the children under five years of age and of 
27/1000 in people aged over 50 years old was observed. Thus, these results bring a new 
concern, since the prevalence curve tends to deviate to the more advanced age groups 
(CDC, 1999). 
The increase of immunity with age, not followed by an increase in the fraction of 
recently infected patients, suggests that patients contact with the viruses, acquiring 
immunity without symptoms. However, although the incidence of recent infection was low 
(only 22 cases), it is important to notice that this study was made in ambulatory regime 
and normally people with symptoms of HAV infection are addressed directly to the 
hospital. 
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1. Abstract:  
Hepatitis C virus (HCV) is a major cause of liver disease worldwide and causes 
substantial morbidity and mortality. The common absence of symptoms associated leads 
to uncertainty to the geographic distribution of this disease. In the absence of a vaccine 
and effective treatment, prevention is extremely important, especially for at risk groups. 
The hepatitis C infection rate was surveyed throughout an eleven-year period by sex and 
age group in Aveiro District. In this retrospective study, blood samples from patients of 
Aveiro District, in ambulatory regime, collected at the Clinical Analysis Laboratory Avelab 
between 2002 and 2012 were screened for the presence of antibodies against HCV 
antigen using a chemiluminescence immunoassay. Approximately 4% of the patients 
presented positive anti-HCV antibodies. The HCV infection was age-dependent and 
varied between sexes (p < 0.05). The number of infected patients decreased during the 
study period (p < 0.05). The results presented in this study indicated that middle-aged 
males are more affected than women which may indicate that this group is more prone to 
risky behaviors. Moreover, the decrease in positive cases during study period may 
indicate a decrease in exposure to risk factors. 
Keywords: hepatitis C, infection, seroprevalence, epidemiology, surveillance study. 
2. Introduction 
HCV infection is associated with a wide spectrum of liver damage, which can 
range from minimal histological changes to liver cirrhosis, hepatocellular carcinoma or 
eventually death (Veldt et al., 2007). The development of cirrhosis is age-dependent and 
the risk is higher when the infection occurs after 40 years old. Approximately 20% of those 
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who develop cirrhosis will suffer hepatocellular carcinoma (Maasoumy and Wedemeyer 
2012). 
The acute hepatitis C is commonly asymptomatic. When symptomatic, it includes 
anorexia, vague abdominal discomfort, nausea and vomiting, fever and fatigue, 
progressing to jaundice in about 25% of patients (Marcellin 1999). Eventually, 60%-90% 
of infected people evolve to chronic disease. Chronic hepatitis is defined as a continuing 
disease without improvement for at least six months (Hsu, 1994). 
In developed countries, before the introduction of routine testing of donated blood, 
the HCV main course of transmission were blood and blood products transfusions. 
Nowadays the illicit use of injectable drugs is the main source of HCV transmission. The 
prevalence of HCV in drug users is higher than that of human immunodeficiency virus 
(HIV) (Champion, Taylor et al. 2004). In developing countries the use of re-used and non-
sterilized syringes and needles in medical procedures is the main cause of transmission 
(Craine, Hickman et al. 2009). Sexual transmission is less common than with Hepatitis B 
virus (HBV) and the risk of perinatal transmission is low (Noorali, Pace et al. 2010). 
The main serological marker is anti-HCV, the presence of anti-HCV antibodies 
cannot be confirmed until 12-27 weeks after exposure, creating a window period of 
seronegativity and elevated risks of infectivity. Genotyping becomes essential in the 
clinical decision on the adoption of appropriate therapy (Saludes et al., 2014). There are 6 
different genotypes numbered 1 to 6 and the sequence can vary 30% to 50% (Noorali, 
2010). The genotype 1b is the most frequent genotype in Europe (WHO, 2014). 
There are seven drugs licensed for the treatment of HCV, standard interferon (IFN) 
or Pegylated interferon alpha (PEG IFN- α), ribavirin (RBV), the protease inhibitors (PIs) 
boceprevir, simeprevir and telaprevir, the nucleotide analog polymerase inhibitor 
sofosbuvir and the most recently licensed treatment ABT-450/r–Ombitasvir and Dasabuvir 
with Ribavirin. The last one is the most effective treatment with a sustained virologic 
response in 90% of cases. The limitations of HCV treatment include high costs, the need 
for sophisticated laboratory tests and trained clinicians, as well as the limited efficacy and 
high toxicity of some of the medicines (Lawitz, Poordad et al. 2014, WHO 2014) 
In Portugal, the combination of Pegylated interferon alpha (PEG IFN- α) and 
ribavirin (RBV) therapy is approved for the treatment of chronic HCV infection in 
individuals with HCV infection of non-1 genotypes (Anjo et al., 2014; Saludes et al., 2014). 
This combination therapy provides recovery in approximately 60% of patients (Velosa et 
al., 2012), however, has serious side effects such as anemia, granulocytopenia, and 
depression, and is associated with long-term treatment and high costs. The effectiveness 
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of the combined PEG IFN-α and RBV therapy is less than 50% for genotype 1, the most 
prevalent genotype (Zhu & Chen, 2013) 
Recent estimates have shown that 185 million people around the world have been 
infected with HCV and 35.0000 die each year. The estimated prevalence of HCV infection 
is highest in Central and East Asia and in the North Africa/Middle East regions. (Figure 5) 
(WHO, 2014). In the European region, 1.1-1.3% of population is infected with HCV 
(Lavanchy 2011). 
In Portugal it is estimated that only 30% of patients are currently diagnosed and 
that the real prevalence of HCV is 1-1.5% (100.000-150.000 individuals). The annual 
costs related to hepatitis C in Portugal are approximately 71 million euros. It is also 
estimated that 60% of infected people have chronic hepatitis C (Anjo et al., 2014). Similar 
to what happens globally, the genotype 1 was the most prevalent genotype in two 
epidemiological studies conducted in Portugal (2001 and 2009), being present in 50-60% 
of patients (VHPB, 2011; Velosa, 2011). According to Anjo et al. (2014) the estimated 
mortality rate in Portugal is 9 deaths per 100.000 inhabitants. In Portugal it is attributed to 
HCV 20% of the total number of deaths due to liver cirrhosis and 50% of the total number 
of deaths from hepatocellular carcinoma (HCC) (Anjo et al., 2014). 
HCV is highly heterogeneous and such heterogeneity is hindering the development 
of an effective vaccine (Rosen and Gretch 1999). 
 Portugal lacks recent epidemiological studies on hepatitis C and it becomes 
important to update this information in order to know the evolution of the disease and 
compare it with other countries in order to decide the best treatment to be applied. 
3. Material and Methods 
3.1. Samples 
In this retrospective study all serum samples analysed for anti-HCV antibodies 
from patients of the District of Aveiro, in ambulatory regime, collected at the Clinical 
Analysis Laboratory Avelab (Aveiro, Portugal) during the period 2002-2012, were 
analysed. The Clinical Analysis Laboratory Avelab comprises delegations located in 14 
municipalities in the district of Aveiro and Coimbra. 
The age and sex of each patient were registered. The study was approved by the 
Ethical Committee of  the Clinical Analysis Laboratory Avelab, specifically by the 
Pharmacist Dr. António Ferreira Neves and Doctors Alberto Ferreira Neves, António 
Rodrigues and Maria Teresa Raposo. 
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3.2. Sampling 
Samples were collected, using the Avelab Laboratory protocol. The venous blood 
of the patients was collected and reserved into a tube with separator spheres allowing clot 
formation. The samples were centrifuged at 1381 x g for 10 minutes. The blood samples 
were analyzed within one hour after collection. When this procedure was not possible the 
samples were stored at 2-8ºC and processed until 24 hours after collection. The samples 
were dismissed 7 days after sampling. 
3.3. Antibodies Detection 
The samples were analyzed in an automated Siemens ADVIA Centaur® XP 
immunoassay analyzer. It was used the acridinium ester (AE) as the chemiluminescent 
label. Samples were diluted in buffer and purified HCV antigen was added forming in the 
presence of specific antibodies immune complexes. AE labeled mouse monoclonal anti-
HCV antibodies, biotinylated mouse monoclonal anti-HCV Fab fragment and streptavidin 
coated paramagnetic capture particles were incubated with the immune complexes. The 
biotinylated conjugate and acridinium labeled conjugate bind to antigen sites not occupied 
by sample HCV antibodies. A magnet is used to separate the microparticles and the 
unbound material is washed. The bound acridinium ester conjugate is then measured by a 
chemiluminescent reaction. The amount of light produced is inversely proportional to the 
antibodies concentration (Siemens, 2006). 
Regarding hepatitis C, the most important screening marker is anti-HCV antibody 
that must be required systematically in individuals who have been exposed to any risk 
situation considered for this infection and is part of laboratory studies for pregnant woman. 
Positive result for anti-HCV antibodies correspond to current or past infection (prevalence 
of infection). It was not possible to distinguish current from past infection. 
3.4. Statistical analysis 
The data were treated using the Statistical Package for the Social Sciences 
(SPSS) 20.0 for Windows. To simplify the statistical analysis the patients were grouped by 
age ranges: 0-5, 6-15, 16-25, 26-35, 36-45, 46-55, 56-65 and >66. The absolute (n) and 
relative (%) frequencies were presented for qualitative variables. The normality of data 
was checked before analysis. As all the variables failed this statistical method assumption, 
the non-parametric Chi-square (X2) test was used to check if the distribution of variables 
was similar in the different groups for immunity. The significance level established was 
0.05. 
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4. Results 
4.1. Characterization of the sample 
The annual average of analyzed samples was 5403. It was observed a decrease 
of about 9% on the number of analysis performed between 2009 and 2012 (Figure 14A). 
From the total of 59440 serum samples analyzed between 2002 and 2012, 18092 (30.4%) 
were performed in male patients and 41348 (69.6%) in females. The age of the patients 
ranged between 0 and 99 years. Patients aged between 26-35 years represented the age 
group that carried out more analysis (Figure 14B). 
From the total serum samples analyzed, 3.7% had positive anti-HCV antibodies 
(Figure 15). 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 14 - Frequency (%) of the samples by year (A) and age group (B) during the study period. 
Figure 15 - Samples classification during study period. 
B A 
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4.2. Characterization of infected or past infected patients 
 The age of patients with positive anti-HCV antibodies ranged from 0 to 99 years, 
with a mean age of 37 years. Anti-HCV antibodies were detected in 2203 patients (636 
females and 1567 males).  
The higher incidence of HCV infection was observed in male patients aged from 
36 to 45 years and in female patients older than 66 years. The incidence of infection was 
significantly different (p < 0.05) among age groups and between genres (Figure 16A) and 
varied over the study period (Figure 16B). 
 
 
 
 
 
 
 
 
 
5. Discussion 
During the study period there was a considerable decrease in the percentage of 
positive results for anti-HCV antibody. In 2002 7.5% of the subjects had been in contact 
with the virus, whereas in 2012 this value decreased to 3% but has stabilized since 2007. 
Anti-HCV antibodies do not distinguish acute from chronic or resolved infection thus is not 
possible to assess the chronic Hepatitis C in the district of Aveiro. The results show a 
decrease in the incidence of the virus during the study period. These results are 
consistent with what has been happening in other industrialized countries, presumably 
reflecting a decrease in percutaneous exposures (Group 2004). 
In studies carried out in Portugal was estimated an incidence of 1-1.5%, which is 
significantly below to that found in Aveiro (Anjo, 2014). 
The incidence rate in males and females was significantly different. Although the 
number of females presented in this study were higher than men, the percentage of 
Figure 16 - Percentage of positive anti-HCV antibodies by genre and age group (A). 
Percentage of anti-HCV antibodies by year (B) 
A 
B 
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incidence of the virus was greater for males in all age groups. The fact that this analysis 
belongs to the general framework of analysis performed by pregnant women may explain 
this difference between male and female incidence. Nevertheless the rate of incidence in 
the 26-35 and 36-45 age groups was 11.2% (603 individuals) and 11.7% (478 individuals), 
respectively, which must not be ignored. The higher incidence in these age groups can be 
explained by the risk behaviors associated with younger people such as drug addiction. In 
United Stated, where the highest prevalence is also among middle aged people, injection 
drug use is responsible for 68% of infections (de Paula 2012, WHO 2014). About 40% of 
people infected older than 40 years old will develop cirrhosis in 20 years, whereas for 
younger patients this value decrease to 20% but it is possible that the fibrosis progression 
in someone infected younger than age 40 years could accelerate as that person ages and 
reaches the age group for which progression to cirrhosis after 20 years of infection is 
higher (Group 2004)(Global Burden of Disease (GBD) for Hepatitis C). 
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Chapter 6 - Conclusions and future perspectives 
 
 This work reports two different themes, one depicts the inactivation efficiency of 
three phage of a highly relevant bacterium in nosocomial infections and the other 
characterizes the District of Aveiro regarding HAV immunity and HCV infection. 
 
 The main conclusions of this work are summarized in the following topics: 
 
 The use of phage therapy with two phages increases the efficiency of phage 
therapy and delays the emergency of phage-resistance suggesting that phage therapy 
can be used to treat urinary tract infections caused by E. cloacae. High efficiency of 
isolated phages combined with long storage periods paves the way for deeper studies and 
possibly in vivo studies. 
 
 The results of the study of HAV immunity in Aveiro suggest a positive impact of 
vaccination of children under 5 years old in the immunity pattern but the rate of immunity 
in the children groups are still quite low indicating that the impact of future infections and 
outbreaks will be substantially more problematic in children than in adults. The decrease 
in the immunity in older patients, associated to the increase in the mortality rate in people 
over 50 years old, suggests that the impact of future infections will be also a concern for 
the elderly group. In the future, cost effectiveness studies of hepatitis A vaccine will be 
important to the decision of introducing universal vaccination of the Portuguese 
population, taking in account that some reports have shown its value in other developed 
countries. 
 
 In the future more accurate epidemiological data on hepatitis C not only in Portugal 
but across the world would be helpful in order to characterize the disease. Ideally these 
studies should be accompanied by more information regarding risk factors and other 
information relating to patients. Despite these difficulties, it can be conclude that there was 
a decline in the prevalence of the disease in the District of Aveiro throughout the study 
period, however, the prevalence is still high when compared with values observed in other 
European countries. It is important to invest more in prevention and public awareness as 
existing treatments, even though effective, are still very expensive and some of them have 
serious side effects. 
 
